

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau






INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : C07H 15/203, A61K 31/70	A1	(11) International Publication Number: WO 96/14325 (43) International Publication Date: 17 May 1996 (17.05.96)
(21) International Application Number: PCT/US95/14795 (22) International Filing Date: 3 November 1995 (03.11.95) (30) Priority Data: 08/335,286 7 November 1994 (07.11.94) US 08/531,142 20 October 1995 (20.10.95) US (71) Applicant: AMERICAN HOME PRODUCTS CORPORATION [US/US]; Five Giralda Farms, Madison, NJ 07940-0874 (US). (72) Inventors: NGUYEN, Thomas, The; 509 West Ashdale Street, Philadelphia, PA 19120 (US). ELLINGBOE, John, Watson; 117 John Street, Ridgewood, NJ 07450 (US). (74) Agents: ALICE, Ronald, W.; American Home Products Corporation, Five Giralda Farms, Madison, NJ 07940-0874 (US) et al.		(81) Designated States: AL, AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KG, KP, KR, KZ, LK, LR, LS, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TT, UA, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, LS, MW, SD, SZ, UG). Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: ACYLATED BENZYLGLYCOSIDES AS INHIBITORS OF SMOOTH MUSCLE CELL PROLIFERATION

(57) Abstract

This invention relates to acylated benzylglycosides and a method for the use of acylated benzylglycosides as smooth muscle cell proliferation inhibitors and as therapeutic compositions for treating diseases and conditions which are characterized by excessive smooth muscle proliferation, such as restenosis. The acylated benzylglycosides of this invention are those of formula (I), where X is (a), (b). R¹ is H, alkyl having 1 to 6 carbon atoms, chloro, bromo, or alkoxy having 1 to 6 carbon atoms; R² is H, an acyl group having 1 to 6 carbon atoms, phenylsulfonyl, or substituted phenylsulfonyl; and R³ is an acyl group having 1 to 8 carbon atoms, benzoyl, substituted benzoyl, alkylsulfonyl having 1 to 6 carbon atoms, phenylsulfonyl, or substituted phenylsulfonyl; R⁴, R⁵, R⁶, R⁷, R⁸, and R⁹ are each, independently, an acyl group having 1 to 6 carbon atoms; and R¹⁰ and R¹¹ are each, independently, an acyl group having 1 to 6 carbon atoms, or the R¹⁰ and R¹¹ groups on the 4' and 6' positions of the maltose or the 4 and 6 positions of the glucose from an isopropylidene group; or pharmaceutically acceptable salts thereof.



FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

- 1 -

**ACYLATED BENZYLGLYCOSIDES AS INHIBITORS
OF SMOOTH MUSCLE CELL PROLIFERATION**

5 This invention relates to acylated benzylglycosides. More particularly, this invention relates to novel acylated benzylglycosides and their use as smooth muscle cell proliferation inhibitors and as therapeutic compositions for treating diseases and conditions which are characterized by excessive smooth muscle proliferation, such as restenosis.

10

Background of the Invention

 All forms of vascular reconstruction such as angioplasty and vein bypass procedures effect a response to injury that ultimately leads to smooth muscle cell (SMC) proliferation and, subsequently, deposition of profuse amounts of extracellular matrix (Clowes, A. W.; Reidy, M. A. *J. Vasc. Surg* 1991, 13, 885). These events are also central processes in the pathogenesis of atherosclerosis (Raines E. W.; Ross R. *Br. Heart J.* 1993, 69 (Supplement), S 30) as well as transplant arteriosclerosis (Isik, F. F.; McDonald, T. O.; Ferguson, M.; Yamanaka, E.; Gordon *Am. J. Pathol.* 1992, 141, 1139). In the case of restenosis following angioplasty, clinically relevant solutions for controlling SMC proliferation through pharmacological intervention have remained elusive to date (Herrman, J. P. R.; Hermans, W. R. M.; Vos, J.; Serruys P. W. *Drugs* 1993, 4, 18 and 249). Any successful approach to selective SMC proliferation inhibition must not interfere with endothelial cell repair or the normal proliferation and function of other cells (Weissberg, P. L.; Grainger, D. J.; Shanahan C. M.; Metcalfe, J. C. *Cardiovascular Res.* 1993, 27, 1191).

 The glycosaminoglycans heparin and heparan sulfate are endogenous inhibitors of SMC proliferation, yet are able to promote endothelial cell growth (Castellot, J. J. Jr.; Wright, T. C.; Karnovsky, M. J. *Seminars in Thrombosis and Hemostasis* 1987, 13, 489). However, the full clinical benefits of heparin, heparin fragments, chemically modified heparin, low molecular weight heparins, and other heparin mimicking anionic polysaccharides may be compromised due to other pharmacological liabilities (excessive bleeding arising from anticoagulation effects, in particular) coupled with heterogeneity of the various preparations (Borman, S. *Chemical and Engineering News*, 1993, June 28, 27). Since the anticoagulant effects of many of these agents are

- 2 -


independent of SMC antiproliferative activity, it would be expected that agents which are more homogenous in composition and of more defined molecular structure would exhibit a more desirable profile with fewer side effects associated with the aforementioned anionic polysaccharides. In the compounds of the present invention, the removal of sulfate groups has been found to depress anticoagulant effects but not affect antiproliferative activity.

Prior Art

- 10 Beta-Cyclodextrin tetradecasulfate has been described as a smooth muscle cell proliferation inhibitor and as an effective inhibitor of restenosis (Reilly, C. F.; Fujita, T.; McFall, R. C.; Stabilito, I. I.; Wai-si E.; Johnson, R. G. *Drug Development Research* 1993, 29, 137). US 5019562 discloses anionic derivatives of cyclodextrins for treating pathological conditions associated with undesirable cell or tissue growth.
- 15 WO 93/09790 discloses antiproliferative polyanionic derivatives of cyclodextrins bearing at least 2 anionic residues per carbohydrate residues. Meinetsberger (EP 312087 A2 and EP 312086 A2) describes the antithrombotic and anticoagulant properties of sulfated bis-alldonic acid amides. US 4431637 discloses polysulfated phenolic glycosides as modulators of the complement system. The compounds of the
- 20 present invention differ from all of the prior art in that the compounds (a) are benzylglycosides which bear no structural resemblance to heparin, sulfated cyclodextrins, or to sulfated lactobionic acid dimers, (b) contain no more than two contiguous sugar residues (dimer), (c) are of defined structure, (d) and are not sulfated.
- 25 Zehavi, U.; Herchman, M. *Carbohydr. Res.* 1986, 151, 371, discloses 4-carboxy-2-nitrobenzyl 4-O- α -D-glucopyranosyl- β -D-glucopyranoside which is attached to a polymer for study as an acceptor in the glycogen synthase reaction. The compounds of the present invention differ from those of the Zehavi disclosure in that
- 30 (a) the substituents on the benzyl groups are different and (b) the use (smooth muscle antiproliferation) is different.


Description of the Invention

This invention describes the composition and utility of acylated benzylglycosides of formula I:



5

where X is



R¹ is H, alkyl having 1 to 6 carbon atoms, halo, CF₃, CN, NO₂, or alkoxy having 1 to 6 carbon atoms;

10

R² is H, an acyl group having 1 to 6 carbon atoms, phenylsulfonyl, or substituted phenylsulfonyl with NO₂; and

R³ is an acyl group having 1 to 8 carbon atoms, benzoyl, substituted benzoyl, alkylsulfonyl having 1 to 6 carbon atoms, phenyl sulphonyl or substituted phenyl sulphonyl,

15

R⁴, R⁵, R⁶, R⁷, R⁸, and R⁹ are each, independently, an acyl group having 1 to 6 carbon atoms; and

R¹⁰ and R¹¹ are each, independently, an acyl group having 1 to 6 carbon atoms, or the R¹⁰ and R¹¹ groups on the 4' and 6' positions of the maltose or the 4 and 6 positions of the glucose form an isopropylidene group;

20


or pharmaceutically acceptable salts thereof.

- 4 -


Preferably R^3 is H, an acyl group having 1 to 8 carbon atoms, alkylsulfonyl having 1 to 6 carbon atoms, benzoyl, benzoyl substituted with NH_2 , NO_2 , CN, C_1 - C_6 alkyl, C_1 - C_6 alkoxy, C_2 - C_{15} acylamino, CF_3 , C_1 - C_6 alkanesulfonylamino, acetyl-(methanesulfonyl)amino, halo, or OH, phenylsulfonyl, or phenylsulfonyl substituted with C_1 - C_6 alkyl, C_1 - C_6 alkoxy, C_2 - C_{15} acylamino, NO_2 , CN, CF_3 , C_1 - C_6 alkanesulfonylamino, acetyl(methanesulfonyl)amino, OH, or halo, wherein the substituted benzoyl or the substituted phenylsulfonyl may be substituted by one or more of the substituents listed, which may be the same or different.

One preferred value of R^2 is phenylsulfonyl substituted with NO_2 .

10 A more preferred aspect or embodiment of this invention are the compounds of formula I:



where X is



15 R^1 is H or alkyl having 1 to 6 carbon atoms;

R^2 is H, an acyl group having 1 to 6 carbon atoms, phenylsulfonyl, or 4-nitrophenylsulfonyl; and

20 R^3 is H, an acyl group having 1 to 8 carbon atoms, benzoyl, benzoyl substituted with nitro, amino, acetamido, 3,5-di-tert-butyl-4-hydroxybenzamido, cyano, or carbomethoxy group, alkylsulfonyl having 1 to 6 carbon atoms, phenylsulfonyl, or phenylsulfonyl substituted with methanesulfonylamino, cyano, trifluoromethyl, alkoxy having 1 to 6 carbon atoms, alkyl having 1 to 6 carbon atoms, chloro, or nitro group wherein the substituted benzoyl or the substituted phenylsulfonyl may be

- 5 -

substituted by one or more of the substituents listed, which may be the same or different.

R⁴, R⁵, R⁶, R⁷, R⁸, and R⁹ are each, independently, an acyl group having 1 to 6 carbon atoms; and

5 R¹⁰ and R¹¹ are each, independently, an acyl group having 1 to 6 carbon atoms, or the R¹⁰ and R¹¹ groups on the 4' and 6' positions of the maltose or the 4 and 6 positions of the glucose form an isopropylidene group;

or pharmaceutically acceptable salts thereof.

The most preferred compounds of this invention are:

- 10 N-[2-methyl-5-(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyloxymethyl)phenyl]-3-nitrobenzamide or a pharmaceutically acceptable salt thereof;
- 3-amino-N-[2-methyl-5-(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyloxymethyl)-phenyl]benzamide or a hydrate or a pharmaceutically acceptable salt thereof;
- 5-(hepta-O-acetyl-β-maltosyloxymethyl)-2-methylphenylamine or a pharmaceutically acceptable salt thereof;
- 15 N-[5-(hepta-O-acetyl-β-D-maltosyloxymethyl)-2-methylphenyl]-3-nitrobenzamide or a pharmaceutically acceptable salt thereof;
- N-[5-(hepta-O-acetyl-β-D-maltosyloxymethyl)-2-methylphenyl]-3-aminobenzamide or a pharmaceutically acceptable salt thereof;
- 20 3-acetylamino-N-[5-(hepta-O-acetyl-β-D-maltosyloxymethyl)-2-methylphenyl]-benzamide or a pharmaceutically acceptable salt thereof;
- N-[3-[2-(hepta-O-acetyl-β-D-maltosyloxymethyl)-6-methylphenylcarbonyl]phenyl]-3,5-di-tert-butyl-4-hydroxybenzamide or a pharmaceutically acceptable salt thereof;
- 25 N-[5-(hepta-O-acetyl-β-D-maltosyloxymethyl)-2-methylphenyl]-3-cyanobenzamide or a pharmaceutically acceptable salt thereof;

- 6 -

- N-[5-(hepta-O-acetyl- β -D-maltosyloxymethyl)-2-methylphenyl]-5-nitroisophthalamic acid methyl ester or a pharmaceutically acceptable salt thereof;
- N-[5-(hepta-O-acetyl- β -D-maltosyloxymethyl)-2-methylphenyl]acetamide or a pharmaceutically acceptable salt thereof;
- 5 N-[5-(hepta-O-acetyl- β -D-maltosyloxymethyl)-2-methylphenyl]propionamide or a pharmaceutically acceptable salt thereof;
- pentanoic acid N-[5-(hepta-O-acetyl- β -D-maltosyloxymethyl)-2-methylphenyl]amide or a pharmaceutically acceptable salt thereof;
- 10 N-[5-(hepta-O-acetyl- β -D-maltosyloxymethyl)-2-methylphenyl]-2,2-dimethyl-propionamide or a pharmaceutically acceptable salt thereof;
- cyclopropanecarboxylic acid N-[5-(hepta-O-acetyl- β -D-maltosyloxymethyl)-2-methylphenyl]amide or a pharmaceutically acceptable salt thereof;
- cyclopentanecarboxylic acid N-[5-(hepta-O-acetyl- β -D-maltosyloxymethyl)-2-methylphenyl]amide or a pharmaceutically acceptable salt thereof;
- 15 N-[5-(hepta-O-acetyl- β -D-maltosyloxymethyl)-2-methylphenyl]-3-cyclopentylpropionamide or a pharmaceutically acceptable salt thereof;
- N-[5-(hepta-O-acetyl- β -D-maltosyloxymethyl)-2-methylphenyl]-4-(methanesulfonylamino)benzenesulfonamide or a pharmaceutically acceptable salt thereof;
- 20 N-[5-(hepta-O-acetyl- β -D-maltosyloxymethyl)-2-methylphenyl]-4-cyanobenzene-sulfonamide or a pharmaceutically acceptable salt thereof;
- N-[5-(hepta-O-acetyl- β -D-maltosyloxymethyl)-2-methylphenyl]-4-trifluoromethylbenzenesulfonamide or a pharmaceutically acceptable salt thereof;
- N-[5-(hepta-O-acetyl- β -D-maltosyloxymethyl)-2-methylphenyl]-3-trifluoromethylbenzenesulfonamide or a pharmaceutically acceptable salt thereof;
- 25 N-[5-(hepta-O-acetyl- β -D-maltosyloxymethyl)-2-methylphenyl]-2-trifluoromethylbenzenesulfonamide or a pharmaceutically acceptable salt thereof;


- 7 -

- N-[5-(hepta-O-acetyl- β -D-maltosyloxymethyl)-2-methylphenyl]-3-(methanesulfonyl-amino)benzenesulfonamide or a pharmaceutically acceptable salt thereof;
- N-[5-(hepta-O-acetyl- β -D-maltosyloxymethyl)-2-methylphenyl]-4-methoxybenzene-sulfonamide or a pharmaceutically acceptable salt thereof;
- 5 N-[5-(hepta-O-acetyl- β -D-maltosyloxymethyl)-2-methylphenyl]-4-methylbenzene-sulfonamide or a pharmaceutically acceptable salt thereof;
- N-[5-(hepta-O-acetyl- β -D-maltosyloxymethyl)-2-methylphenyl]-4-chlorobenzene-sulfonamide or a pharmaceutically acceptable salt thereof;
- 10 N-[5-(hepta-O-acetyl- β -D-maltosyloxymethyl)-2-methylphenyl]-4-chloro-3-nitrobenzenesulfonamide or a pharmaceutically acceptable salt thereof;
- N-[5-(hepta-O-acetyl- β -D-maltosyloxymethyl)-2-methylphenyl]methanesulfonamide or a pharmaceutically acceptable salt thereof;
- butane-1-sulfonic acid N-[5-(hepta-O-acetyl- β -D-maltosyloxymethyl)-2-methylphenyl]-amide or a pharmaceutically acceptable salt thereof;
- 15 4-(hepta-O-acetyl- β -D-maltosyloxymethyl)-2-methylphenylamine hydrochloride or a pharmaceutically acceptable salt thereof;
- N-[4-(hepta-O-acetyl- β -D-maltosyloxymethyl)-2-methylphenyl]-4-(methanesulfonyl-amino)benzenesulfonamide or a pharmaceutically acceptable salt thereof;
- N-[4-(hepta-O-acetyl- β -D-maltosyloxymethyl)-2-methylphenyl]-4-nitro-N-(4-nitro-phenylsulfonyl)benzenesulfonamide or a pharmaceutically acceptable salt thereof;
- 20 N-acetyl-4-[acetyl(methanesulfonyl)amino]-N-[5-(4',6'-O-isopropylidene-2,2',3,3',6-penta-O-acetyl- β -D-maltosyloxymethyl)-2-methylphenyl]benzenesulfonamide or a pharmaceutically acceptable salt thereof;
- 25 N-propionyl-4-[propionyl(methanesulfonyl)amino]-N-[5-(hepta-O-propionyl- β -D-maltosyloxymethyl)-2-methylphenyl]benzenesulfonamide or a pharmaceutically acceptable salt thereof.

Process of the Invention

The compounds of the present invention can be prepared according to the general sequence of reactions outlined in the Schemes below:

Scheme I



5


where R^1 , R^2 , and R^3 are as defined above.

- 9 -

- Thus, maltosyl bromide 1 is coupled with a benzyl alcohol 2 in the presence of a catalyst such as a mercuric bromide, mercuric cyanide, silver triflate, or silver perchlorate in an aprotic solvent such as dichloromethane, ether, toluene, or nitromethane at temperatures ranging from -40 °C to reflux to yield glycoside 3.
- 5 Reduction of the nitro group of 3 can be accomplished with a reducing agent such as stannous chloride in a polar aprotic solvent such as ethyl acetate at ambient temperature to reflux, or by catalytic hydrogenation in the presence of a catalyst such as palladium on carbon gives an anilino compound 4. Coupling of 4 with an acid chloride or sulfonyl chloride can be completed in the presence of an amine base such as
- 10 triethylamine or diisopropylethylamine in an aprotic solvent such as dichloromethane or tetrahydrofuran at temperatures ranging from -20 °C to ambient temperature yields the target compounds 5. The same sequence of reactions can be used starting with bromoglucose tetraacetate to yield the glucose analogue of 5.

- 10 -

Scheme II



As illustrated in Scheme II, wherein R^1 , R^2 and R^3 are as defined above and R^{12} is an acyl group having from 1 to 6 carbon atoms, the acetate groups of 5 can be replaced by hydrolysis with a base such as sodium methoxide in methanol or aqueous sodium hydroxide in methanol at ambient temperature to reflux to yield 6 and reacylation with an acyl anhydride in the presence of an amine base such as pyridine at temperatures ranging from 0 °C to ambient temperature to yield 7. Alternatively, after hydrolysis of the acetate groups, the 4 and 6 hydroxy groups of glucose or the 4' and

- 11 -

6' hydroxy groups of maltose can be reacted with dimethoxypropane in the presence of an acid catalyst such as camphorsulfonic acid in a polar aprotic solvent such as acetonitrile at ambient temperature to yield an isopropylidene derivative 8.

5 This invention is also directed to pharmaceutical compositions comprised of acylated benzylglycosides either alone or in combination with excipients (i.e. pharmaceutically acceptable materials with no pharmacological effect). Such compositions are useful for diseases or conditions which are characterized by excessive
10 smooth muscle cell proliferation most frequently arising from vascular reconstructive surgery and transplantation, for example, balloon angioplasty, vascular graft surgery, coronary artery bypass surgery, and heart transplantation. Other disease states in which there is unwanted vascular proliferation include hypertension, asthma, and congestive heart failure. The compounds of the invention are thus useful for treating these diseases and states.

15 The compounds of this invention may be administered systemically, for example by intravenous injection, typically ranging from 0.1 to 10 mg/kg/h over 5 - 30 days, or by subcutaneous injection at lower dose, by oral administration at higher dose than intravenous injection. Localized delivery of the compounds of this invention may
20 also be achieved by transmembrane, transdermal, or other topical administrative routes using appropriate continuous release devices such as supporting matrix, where applicable. The compositions of the invention may be formulated with conventional excipients, such as a filler, a disintegrating agent, a binder, a lubricant, a flavoring agent and the like. These are formulated in a conventional manner. It is understood
25 that the compounds of this invention may be administered in any manner and at any concentration that is efficacious to the particular recipient. The manner of delivery and composition and concentration of the pharmaceutical dose will be determined on an individual basis by the physician or other skilled medical professional treating the
30 recipient.

- 12 -

Effects on Cell Proliferation

A. Cell Sources

5 The ability of the compounds of the present invention to inhibit smooth muscle cell proliferation was established using isolated aortic cells. Porcine aortas were received from a local slaughterhouse and were iced during transit. The aorta was scrupulously cleansed of fatty tissue and rinsed in sterile phosphate-buffered saline with 2% antibiotic/antimycotic (Gibco catalog # 600 - 5240 AG). The tissue was then
10 digested in 10 - 15 mL of "Enzyme Mixture" containing collagenase type I, 165 U/mL; elastase type III, 15 U/mL; BSA, 2 mg/mL; and soybean trypsin inhibitor, 0.375 mg/mL followed by incubation at 37 °C under 5% CO₂ for 10 - 15 min. After this treatment, the outer surface adventitia was easily removed by peeling with forceps. The aorta was then longitudinally cut and laid open and the endothelial layer was removed
15 by scraping.

 The medial layer of cells was rinsed in enzyme solution, and placed in a new 100 mm dish with 10 mL of enzyme solution. The aorta was minced using a fine pair of scissors and digested for 2 - 3 h at 37 °C in 30 mL of fresh enzyme solution. After
20 digestion, the tissue was homogenized using a sterile Pasteur pipette with a fire polished tip or an eppendorf pipetter with a 200 - 1000 µL sterile pipette tip. The suspension was then centrifuged for 10 minutes at 8000 rpm and the pellet was suspended in 4 - 6 mL of fresh medium and plated onto 4 - 6 100 mm flasks with vented caps. Cells were allowed to grow to confluence and split using 0.25 % trypsin.
25 Cells were evaluated for purity and overall quality using antibody to SMC actin.

B. Examination of the Effects of Compounds on Cell Proliferation Using ³H Thymidine Incorporation

30 Cells were assayed in early passage (generally passage 3 - 7) at sub-confluent conditions. Cultures were grown in 16 mm (24 well) multi-well culture dishes in medium 199 supplemented with 10% fetal bovine serum and 2% antibiotic/antimycotic. At sub-confluence, the cells were placed in a defined serum free medium (AIM-V; Gibco) for 24 - 48 h prior to initiating the experimental protocol.

35

- 13 -

Although compounds were found to be more effective with longer pre-incubations, in general, experiments were initiated with the addition of compound, ^3H thymidine and serum / growth factor to serum deprived synchronized cells and results are reported in this invention accordingly.

5

Compounds were added to each well at 50 fold dilution (20 μL / well) and the plates were incubated for 24 - 36 h at 37 $^{\circ}\text{C}$ in 5% CO_2 . Compounds were initially dissolved in 50% ethanol and serially diluted into media. Compounds were routinely assayed at concentrations from 1 to 100 μM . As a control, grade II porcine intestinal
10 mucosal heparin (sodium salt) from Sigma (H-7005) was routinely assayed in all cell preparations at concentrations from 0.1 to 100 $\mu\text{g/mL}$.

At the completion of the experiment, plates were placed on ice, washed three times with ice cold phosphate buffered saline (PBS) and incubated in ice cold 10%
15 trichloroacetic acid (TCA) for 30 minutes to remove acid soluble proteins. Solution was transferred to scintillation vials containing 0.4 N HCl (500 μL /vial to neutralize NaOH) and each well was rinsed two times with water (500 μL) for a total volume of 2 mL/vial.

Data was obtained, in triplicate, for both control and experimental samples. Control (100%) data was obtained from maximally stimulated cells, as the result of growth factor or serum stimulation. Experimental data was obtained from cells maximally stimulated with growth factor or serum and treated with compound. Data was expressed as a percent of control from which a percent inhibition or IC_{50} could be
25 determined. Results for the compounds of Examples 1-33 for serum stimulated assays are reported in Table I below.

C. Cytotoxicity

30 Visually, all cells were found to tolerate high levels of all compounds quite well, however to insure that no toxicity was present, cytotoxicity of compounds was examined using a commercial modification of the MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) assay. Briefly, cells were again grown in 24 well plates to 70 - 80 % confluency and, as before, serum deprived for 24 - 48 h prior to
35 initiation of the experimental protocol. To insure that the MTT assay monitored toxicity

- 14 -

rather than proliferation, cells were incubated with 100 µg/mL of drug in fresh medium without serum for 24 h at 37 °C in a humidified CO₂ incubator. Upon completion of the compound treatment, MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) indicator dye was added for 4 h at 37 °C. Cells were then lysed and aliquots
5 from each well were transferred to a 96 well plate for analysis. Absorbance at 570 nm wavelength with a reference wavelength of 630 nm was recorded using an ELISA plate reader. Results were determined as percent viable using no drug (100% viable) and pre-solubilization (0% viable) standards. The compounds of Examples 3, 6, 11, 12, 14, 15, 16, and 17 exhibited no toxicity at up to 100 µg/mL.

10

Anticoagulant Activity

The anticlotting activity of the compounds of this invention was evaluated in a partial thromboplastin time (APTT) assay using normal human plasma collected from 5
15 donors according to the procedure of Fenichel et. al. (*Clin. Chem.* 1964, 10, 69). A BBL Fibrometer automatic precision coagulation timer utilizing a 0.3 mL probe was employed. An Ellagic acid activated partial thromboplastin was used for these experiments. This reagent was added to human citrated plasma equilibrated at 37 °C in a plastic well in the clot timer. Calcium at 37 °C was added, the clot timer was started
20 and the time for fibrin clot formation (in seconds) was recorded. The effect of the compounds, added to plasma, over a concentration of 12.5 - 200 µg/mL was determined. Any plasma which did not clot after 240 seconds was assigned a clotting time of 240 seconds. An unfractionated heparin comparator was used over the concentration range of 1.25 - 10 µg/mL. Clotting tests at all concentrations were run in
25 triplicate. Analysis of variance for a randomized block design was used to determine the significance of differences observed in the clotting times. The compounds of this invention showed no anticoagulation activity at concentrations up to 200 µg/mL.

Table I. Smooth Muscle Antiproliferation Activity and Anticoagulation Activity

5

Compound of Example	Porcine Smooth Muscle Cell Antiproliferation IC ₅₀ or (% Inhibition at x concentration)
1	79% inhibition at 50 µg/mL
2	23% inhibition at 50 µg/mL
3	5.08 µM
4	13% inhibition at 50 µg/mL
5	44% inhibition at 50 µg/mL
6	18.3 µM
7	185.4 µM
8	37.1 µM
9	14.6 µM
10	64.0 µM
11	20.4 µM
12	4.8 µM
13	44.3 µM
14	48.4 µM
15	46.7 µM
16	37.8 µM
17	26.5 µM
18	19.0 µM
19	4.0 µM
20	9.3 µM
21	40.0 µM
22	25.4 µM
23	28.0 µM

Table I Continued

Compound of Example	Porcine Smooth Muscle Cell Antiproliferation IC ₅₀ or (% Inhibition at x concentration)
24	61% inhibition at 40 μ M
25	10.0 μ M
26	23.1 μ M
27	22.4 μ M
28	9.0 μ M
29	70% inhibition at 40 μ M
30	13.8 μ M
31	37% inhibition at 100 μ M
32	6.2 μ M
33	30% inhibition at 20 μ M
heparin (H-7005)	45 - 83% inhibition at 50 μ g/mL

The compounds of Examples 3, 11, 12 and 17 exhibited no anticoagulant activity (APTT assay).

Specific procedures are described in the following examples. These examples are given to illustrate the invention and should not be construed as limiting the invention set forth in the appended claims.

- 17 -

EXAMPLE 1**N-[2-Methyl-5-(2,3,4,6-tetra-O-acetyl- β -D-glucopyranosyloxymethyl)phenyl]-3-nitrobenzamide**

5

Step 1**N-(5-Hydroxymethyl-2-methylphenyl)-3-nitrobenzamide**

To a stirred, cooled (0 °C) mixture of 3-amino-4-methylbenzyl alcohol (10.0 g, 0.072 mol) and pyridine (5.8 g, 0.072 mol) in THF (100 mL) was added 3-nitrobenzoyl chloride (13.5 g, 0.072 mol). After 2 h, the mixture was concentrated, suspended in water and filtered to give a brown solid. Trituration with hot EtOH gave 18.8 g (90%) of product as a white solid, mp 198-200 °C; ¹H NMR (DMSO-*d*₆) δ 2.20 (s, 3 H), 4.46 (s, 2 H), 7.12 (dd, J = 7.8 Hz, 1.5 Hz, 1 H), 7.25 (dd, J = 7.8, 1.5 Hz, 1 H), 7.82 (m, 1 H), 8.41 (m, 2 H), 8.78 (s, 1 H), 10.26 (s, 1 H).

15

Step 2**N-[2-Methyl-5-(2,3,4,6-tetra-O-acetyl- β -D-glucopyranosyloxymethyl)-phenyl]-3-nitrobenzamide**

20

A mixture of N-(5-hydroxymethyl-2-methylphenyl)-3-nitrobenzamide (10.0 g, 0.034 mol), HgBr₂ (10.0 g, 0.041 mol), Hg(CN)₂ (15.0 g, 0.058 mol), and α -D-glucopyranosyl bromide tetraacetate (17.2 g, 0.042 mol) in nitromethane (200 mL) was heated under reflux for 4 h. 2.0 M KBr was added and the mixture was stirred for 30 minutes and extracted with EtOAc. The combined extracts were washed with saturated aqueous NaHCO₃ and brine, dried (MgSO₄), and concentrated to give 12.0 g (56%) of product as a brown foam; ¹H NMR (DMSO-*d*₆) δ 2.00 (m, 12 H), 2.21 (s, 3 H), 4.00 (m, 2 H), 4.20 (dd, J = 12.4, 5.0 Hz, 1 H), 4.58 (d, J = 12.4 Hz, 1 H), 4.82 (m, 4 H), 5.27 (t, J = 9.3 Hz, 1 H), 7.10 (d, J = 7.8 Hz, 1 H), 7.24 (d, J = 7.8 Hz, 1 H), 7.25 (s, 1 H), 7.81 (m, 1 H), 8.42 (m, 2 H), 8.80 (s, 1 H), 10.60 (s, 1 H).

30

EXAMPLE 2**3-Amino-N-[2-methyl-5-(2,3,4,6-tetra-O-acetyl- β -D-glucopyranosyloxymethyl)phenyl]benzamide**

5

A solution of N-[2-methyl-5-(2,3,4,6-tetra-O-acetyl- β -D-glucopyranosyloxymethyl)phenyl]-3-nitrobenzamide (2.0 g, 3.244 mmol), prepared as described in Example 1, in MeOH (15 mL) was hydrogenated over 10% Pd/C (1.0 g) at atmospheric pressure for 18 h. The mixture was filtered through solka floc and the filtrate was concentrated. Purification by flash chromatography (1% MeOH/CH₂Cl₂) gave 1.30 g (68%) of product as a white solid, mp 94-96 °C; ¹H NMR (DMSO-*d*₆) δ 2.00 (m, 12 H), 2.21 (s, 3 H), 4.03 (m, 1 H), 4.06 (d, J = 2.3 Hz, 1 H), 4.20 (dd, J = 12.4, 5.0 Hz, 1 H), 4.55 (d, J = 12.4 Hz, 1 H), 4.75 (d, J = 12.4 Hz, 1 H), 4.90 (m, 3 H), 5.27 (t, J = 9.3 Hz, 1 H), 5.28 (s, 2 H), 6.72 (m, 1 H), 7.10 (m, 4 H), 7.23 (d, J = 7.9 Hz, 1 H), 7.27 (d, J = 1.45 Hz, 1 H), 9.63 (s, 1 H).

15

EXAMPLE 3**5-(Hepta-O-acetyl- β -maltosyloxymethyl)-2-methylphenylamine**

20

Step 1**5-(Hepta-O-acetyl- β -maltosyloxymethyl)-2-methyl-1-nitrobenzene**

To a mixture of 4-methyl-3-nitrobenzyl alcohol (4.0 g, 24.0 mmol) and acetobromo- α -maltose (20.0 g, 29.0 mmol) in CH₃NO₂ (60 mL) was added Hg(CN)₂ (6.15 g, 24.0 mmol) and HgBr₂ (6.91 g, 19.0 mmol). After stirring at ambient temperature overnight, brine was added and the mixture was stirred for 20 min. The reaction mixture was extracted with CH₂Cl₂. The organic phase was washed with brine, dried (MgSO₄), and concentrated. Purification by flash chromatography (1 : 2 and 1 : 1 EtOAc / petroleum ether) and rechromatography using ether / petroleum ether (3 : 1, then 4 : 1, then 100 : 0) gave 7.97 g of the title compound as a colorless solid; ¹H NMR (CDCl₃) δ 2.00 (s, 3 H), 2.01 (s, 3 H), 2.03 (s, 6 H), 2.04 (s, 3 H), 2.11 (s, 3 H), 2.16 (s, 3 H), 2.60 (s, 3 H), 3.65- 3.71 (m, 1 H), 3.9 - 4.1 (m, 3 H), 4.2 - 4.3 (m, 2 H), 4.54 (dd, 1 H), 4.62 (d, 1 H), 4.65 (d, 1 H), 4.8 - 5.0 (m, 3 H), 5.06

25

30

- 19 -

(t, 1 H), 5.25 (t, 1 H), 5.25 (t, 1 H), 5.36 (t, 1 H), 5.42 (d, 1 H), 5.42 (d, 1 H), 7.32 (d, 1 H), 7.41 (d, 1 H), 7.92 (s, 1 H).

Step 2**5 5-(Hepta-O-acetyl- β -maltosyloxymethyl)-2-methylphenylamine**

Procedure A: A mixture of 5-(hepta-O-acetyl- β -maltosyl-oxymethyl)-2-methyl-1-nitrobenzene (4.0 g, 5.1 mmol) and $\text{SnCl}_2 \cdot \text{H}_2\text{O}$ (8.00 g, 35.0 mmol) in EtOAc (100 mL) was heated under reflux for 2 h. The reaction mixture was cooled to
10 room temperature and saturated aqueous NaHCO_3 was added. After stirring for 15 minutes, the mixture was diluted with CH_2Cl_2 (200 mL) and filtered through solka floc. The organic phase was dried (MgSO_4) and concentrated. Purification by flash chromatography (EtOAc / CH_2Cl_2 , 1 : 5, then 1 : 4, then 1 : 2, then 1 : 1) gave 3.42 g (89%) of 5-(hepta-O-acetyl- β -maltosyloxymethyl)-2-methylphenylamine as a colorless
15 foam; ^1H NMR (CDCl_3) δ 1.99 (s, 6 H), 2.00 (s, 3 H), 2.03 (s, 6 H), 2.11 (s, 3 H), 2.17 (s, 6 H), 3.63 - 3.67 (m, 1 H), 3.95 - 4.01 (m, 3 H), 4.26 (dd, 2 H), 4.51 (d, 1 H), 4.54 (d, 1 H), 4.75 (d, 1 H), 4.82 - 4.90 (m, 2 H), 5.05 (t, 1 H), 5.20 (t, 1 H), 5.39 (t, 1 H), 5.41 (d, 1 H), 6.62 (d, 1 H), 6.63 (s, 1 H), 7.01 (d, 1 H).

20 A hydrochloride salt was prepared by treating a solution of similarly prepared free base (5.94 g, 7.86 mmol) in ether (300 mL) with saturated ethereal HCl (100 mL). The precipitate was collected by filtration to give 4.83 g (78%) of the title compound hydrochloride salt as a white solid, mp 124-130 °C.

25 **Procedure B:** A solution of 5-(hepta-O-acetyl- β -maltosyl-oxymethyl)-2-methyl-1-nitrobenzene (31.1 g, 39.6 mmol) was hydrogenated at 50 psi over 10% Pd/C (10.0 g) for 1 h. The catalyst was removed by filtration and the filtrate was concentrated to give a white foam. Trituration with water gave 28.0 g (94%) of 5-(hepta-O-acetyl- β -maltosyloxymethyl)-2-methylphenylamine as a white solid, mp 154 - 156 °C.

30

EXAMPLE 4**N-[5-(Hepta-O-acetyl-β-D-maltosyloxymethyl)-2-methylphenyl]-3-nitrobenzamide**

5 To a stirred mixture of 5-(hepta-O-acetyl-β-D-maltosyloxymethyl)-2-methylphenylamine (1.90 g, 2.52 mmol), prepared according to Example 3, and pyridine (0.22 g, 2.77 mmol) in CH₂Cl₂ (10 mL) was added 3-nitrobenzoyl chloride (0.51 g, 2.77 mmol). After 18 h, the mixture was diluted with EtOAc, washed with saturated
10 aqueous NaHCO₃, H₂O, and brine, dried (MgSO₄), and concentrated. Purification by flash chromatography (1 : 1 EtOAc / hexane) gave 2.00 g (88%) of product as a white foam; ¹H NMR (DMSO-*d*₆) δ 2.00 (m, 21 H), 2.20 (s, 3 H), 4.00 (m, 4 H), 4.19 (m, 2 H), 4.40 (dd, 1 H), 4.56 (d, 1 H), 4.75 (m, 2 H), 4.80 (m, 1 H), 4.85 (d, 1 H), 5.05 (t, 1 H), 5.20 (t, 1 H), 5.30 (m, 2 H), 7.10 (d, 1 H), 7.25 (s, 1 H), 7.28 (d, 1
15 H), 7.84 (m, 1 H), 8.42 (d, 1 H), 8.45 (dd, 1 H), 8.80 (s, 1 H), 10.28 (s, 1 H). Anal. Calcd. for C₄₁H₄₈N₂O₂₁: C, 54.42; N, 5.35; H, 3.10. Found: C, 54.30; H, 5.27; N, 3.10.

EXAMPLE 5

20 **N-[5-(Hepta-O-acetyl-β-D-maltosyloxymethyl)-2-methylphenyl]-3-aminobenzamide**

A solution of N-[5-(hepta-O-acetyl-β-D-maltosyloxymethyl)-2-methylphenyl]-
25 3-nitrobenzamide (0.55 g, 0.608 mmol), prepared as described in Example 4, in EtOAc (10 mL) was hydrogenated at atmospheric pressure over 10% Pd/C (0.20 g) for 2 h. The mixture was filtered and the filtrate was concentrated. Purification by flash chromatography (50% EtOAc/hexane) and trituration with ether/hexane gave 0.30 g (56%) of product as a white solid, mp 116-118 °C.

EXAMPLE 6**3-Acetylamino-N-[5-(hepta-O-acetyl-β-D-maltosyloxymethyl)-2-methylphenyl]benzamide**

5

To a mixture of 3-amino-N-[2-methyl-5-(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyloxymethyl)phenyl]benzamide (0.85 g, 0.95 mmol), prepared as described in Example 5, and pyridine (0.10 g, 1.15 mmol) in THF (10 mL) was added acetyl chloride (0.10 g, 1.15 mmol). After 2 h, the mixture was concentrated, suspended in
10 water, and filtered to give a white solid. Recrystallization from EtOAc/hexane gave 0.60 g (71%) of product as a white solid, mp 130-132°C; ¹H NMR (DMSO-*d*₆) δ 1.92 (s, 6 H), 1.94 (s, 3 H), 1.97 (s, 3 H), 2.05 (s, 9 H), 2.21 (s, 3 H), 4.00 (m, 4 H), 4.20 (m, 2 H), 4.40 (dd, J = 12.2, 1.9 Hz, 1 H), 4.54 (d, J = 12.2 Hz, 1 H), 4.73 (m, 2 H), 4.86 (dd, J = 10.6, 3.7 Hz, 2 H), 4.97 (t, J = 9.9 Hz, 1 H), 5.21 (t, J = 9.9 Hz, 1 H), 5.27 (t, J = 9.9 Hz, 1 H), 5.29 (d, J = 3.7 Hz, 1 H), 7.04 (d, J = 7.9 Hz, 1 H), 7.06 (dd, J = 7.9, 1.2 Hz, 1 H), 7.09 (s, 1 H), 7.44 (m, 1 H), 7.61 (d, J = 7.9 Hz, 1 H), 7.82 (dd, J = 8.5, 1.7 Hz, 1 H), 8.08 (m, 1 H), 9.84 (s, 1 H), 10.11 (s, 1 H). Anal. Calcd. for C₄₃H₅₂N₂O₂₀: C, 56.33; H, 5.72; N, 3.05.
Found: C, 56.16; H, 5.79; N, 3.02.

20

EXAMPLE 7**N-[3-[2-(Hepta-O-acetyl-β-D-maltosyloxymethyl)-6-methylphenyl]carbamoyl]phenyl]-3,5-di-tert-butyl-4-hydroxybenzamide**

25

The title compound was prepared according to the procedure of Example 4 as a white solid, mp 158-160 °C; ¹H NMR (DMSO-*d*₆) δ 1.43 (s, 18 H), 1.94 (s, 3 H), 1.97 (s, 6 H), 1.98 (s, 6 H), 2.01 (s, 3 H), 2.08 (s, 3 H), 2.22 (s, 3 H), 4.00 (m, 4 H), 4.20 (m, 2 H), 4.39 (dd, J = 12.0, 2.3 Hz, 1 H), 4.48 (d, J = 12.4 Hz, 1 H),
30 4.69 (d, J = 12.0 Hz, 1 H), 4.72 (t, J = 12.4 Hz, 1 H), 4.82 (d, J = 8.1 Hz, 1 H), 4.87 (dd, J = 10.6, 3.9 Hz, 1 H), 4.98 (t, J = 9.9 Hz, 1 H), 5.21 (t, J = 9.9 Hz, 1 H), 5.28 (m, 2 H), 7.11 (dd, J = 7.7, 1.4 Hz, 1 H), 7.22 (d, J = 7.7 Hz, 1 H), 7.25 (s, 1 H), 7.49 (t, J = 7.9 Hz, 1 H), 7.53 (s, 1 H), 7.70 (m, 3 H), 8.00 (d, J = 7.9 Hz, 1 H), 8.22 (s, 1 H), 9.89 (s, 1 H), 10.21 (s, 1 H). Anal. Calcd. for C₅₆H₇₀N₂O₂₁: C, 60.75; H, 6.37; N, 2.53. Found: C, 60.63; H, 6.40; N, 2.46.

35

EXAMPLE 8**N-[5-(Hepta-O-acetyl-β-D-maltosyloxymethyl)-2-methylphenyl]-3-cyanobenzamide**

5

The title compound was prepared according to the procedure of Example 4 as a white solid, mp 116-118 °C; ¹H NMR (DMSO-*d*₆) δ 1.91 (s, 3 H), 1.93 (s, 3 H), 1.94 (s, 3 H), 1.97 (s, 6 H), 2.01 (s, 3 H), 2.07 (s, 3 H), 2.22 (s, 3 H), 3.90 (m, 4 H), 4.19 (m, 2 H), 4.38 (dt, J = 1.24, 11.4 Hz, 1 H), 4.55 (d, J = 12.2 Hz, 1 H), 4.72 (m, 2 H), 4.84 (t, J = 6.2 Hz, 1 H), 4.86 (d, J = 8.3 Hz, 1 H), 4.95 (t, J = 9.9 Hz, 1 H), 5.21 (t, J = 9.9 Hz, 1 H), 5.26 (d, J = 3.7 Hz, 1 H), 5.31 (t, J = 9.9 Hz, 1 H), 7.09 (dd, J = 7.7, 0.8 Hz, 1 H), 7.26 (d, J = 0.8 Hz, 1 H), 7.28 (d, J = 7.7 Hz, 1 H), 7.75 (m, 1 H), 8.06 (d, J = 7.7 Hz, 1 H), 8.25 (d, J = 7.9 Hz, 1 H), 8.38 (s, 1 H), 10.08 (s, 1 H). Anal. Calcd. for C₄₂H₄₈N₂O₁₉: C, 57.03; H, 5.47; N, 3.16. Found: C, 56.80; H, 5.45; N, 3.06.

10

15

EXAMPLE 9**N-[5-(Hepta-O-acetyl-β-D-maltosyloxymethyl)-2-methylphenyl]-5-nitroisophthalamic Acid Methyl Ester**

20

The title compound was prepared according to the procedure of Example 4 as a white solid, mp 110-112 °C; ¹H NMR (DMSO-*d*₆) δ 1.94 (s, 3 H), 1.97 (s, 6 H), 1.98 (s, 6 H), 2.01 (s, 3 H), 2.08 (s, 3 H), 2.22 (s, 3 H), 4.00 (m, 7 H), 4.20 (m, 2 H), 4.39 (dd, J = 12.0, 2.3 Hz, 1 H), 4.48 (d, J = 12.4 Hz, 1 H), 4.82 (d, J = 8.1 Hz, 1 H), 4.87 (dd, J = 10.6, 3.9 Hz, 1 H), 4.98 (t, J = 9.9 Hz, 1 H), 5.21 (t, J = 9.9 Hz, 1 H), 5.28 (m, 2 H), 7.13 (dd, J = 7.7, 1.4 Hz, 1 H), 7.26 (s, 1 H), 7.28 (d, J = 7.7 Hz, 1 H), 8.79 (m, 1 H), 8.91 (m, 1 H), 9.03 (m, 1 H), 10.51 (s, 1 H). Anal. Calcd. for C₄₃H₅₀N₂O₂₃: C, 53.64; H, 5.23; N, 2.91. Found: C, 53.70; H, 5.16; N, 2.65.

25

30

EXAMPLE 10**N-[5-(Hepta-O-acetyl- β -D-maltosyloxymethyl)-2-methylphenyl]acetamide**

5

To a mixture of 5-(hepta-O-acetyl- β -maltosyloxymethyl)-2-methylphenylamine (2.00 g, 2.65 mmol), prepared as described in Example 3, and triethylamine (0.80 g, 7.94 mmol) in CH_2Cl_2 (20 mL) was added acetyl chloride dropwise. After 3 h, water was added and the layers were separated. The organic layer was washed with brine, dried (MgSO_4), and concentrated to give an off-white foam. Purification by flash chromatography (40% to 60% EtOAc/hexane) gave a white foam. Trituration with ether/hexane gave 1.79 g (85%) of product as a white solid, mp 90-92 °C; ^1H NMR ($\text{DMSO}-d_6$) δ 1.92 (s, 3 H), 1.93 (s, 3 H), 1.94 (s, 3 H), 1.97 (s, 6 H), 2.01 (s, 3 H), 2.03 (s, 3 H), 2.09 (s, 3 H), 2.17 (s, 3 H), 4.00 (m, 4 H), 4.20 (m, 2 H), 4.39 (dd, J = 11.4, 1.1 Hz, 1 H), 4.49 (d, J = 12.0 Hz, 1 H), 4.68 (d, J = 12.0 Hz, 1 H), 4.70 (t, J = 9.8 Hz, 1 H), 4.82 (d, J = 8.9 Hz, 1 H), 4.86 (dd, J = 10.6, 3.9 Hz, 1 H), 4.98 (t, J = 9.8 Hz, 1 H), 5.02 (t, J = 9.8 Hz, 1 H), 5.26 (m, 2 H), 6.96 (d, J = 7.9 Hz, 1 H), 7.16 (d, J = 7.9 Hz, 1 H), 7.32 (s, 1 H), 9.26 (s, 1 H). Anal. Calcd. for $\text{C}_{36}\text{H}_{47}\text{NO}_{19}$: C, 54.20; H, 5.94; N, 1.76. Found: C, 54.26; H, 5.95; N, 1.96.

20

EXAMPLE 11**N-[5-(Hepta-O-acetyl- β -D-maltosyloxymethyl)-2-methylphenyl]propionamide**

25

The title compound was prepared according to the procedure of Example 10 as a white foam; ^1H NMR ($\text{DMSO}-d_6$) δ 1.08 (t, J = 7.5 Hz, 3 H), 1.92 (s, 3 H), 1.93 (s, 3 H), 1.94 (s, 3 H), 1.97 (s, 3 H), 1.98 (s, 3 H), 2.02 (s, 3 H), 2.09 (s, 3 H), 2.16 (s, 3 H), 2.32 (q, J = 7.5 Hz, 2 H), 3.96 (m, 4 H), 4.18 (m, 2 H), 4.39 (dd, J = 12.0, 1.9 Hz, 1 H), 4.49 (d, J = 12.5 Hz, 1 H), 4.71 (m, 2 H), 4.83 (m, 2 H), 4.98 (t, J = 9.8 Hz, 1 H), 5.21 (t, J = 9.8 Hz, 1 H), 5.28 (m, 2 H), 6.97 (d, J = 8.1 Hz, 1 H), 7.17 (d, J = 8.1 Hz, 1 H), 7.31 (s, 1 H), 9.19 (s, 1 H). Anal. Calcd. for $\text{C}_{37}\text{H}_{49}\text{NO}_{19}$: C, 54.74; H, 6.08; N, 1.72. Found: C, 54.38; H, 6.06; N, 1.74.

30

EXAMPLE 12**Pentanoic Acid N-[5-(Henta-O-acetyl- β -D-maltosyloxymethyl)-2-methylphenyllamide**

5 The title compound was prepared according to the procedure of Example 10 as a white foam; ^1H NMR ($\text{DMSO-}d_6$) δ 0.90 (t, $J = 7.3$ Hz, 3 H), 1.33 (m, 2 H), 1.57 (m, 2 H), 1.92 (s, 3 H), 1.93 (s, 3 H), 1.94 (s, 3 H), 1.97 (s, 3 H), 1.98 (s, 3 H), 2.02 (s, 3 H), 2.09 (s, 3 H), 2.16 (s, 3 H), 2.31 (t, $J = 7.3$ Hz, 2 H), 3.94 (m, 4 H),
10 4.19 (m, 2 H), 4.39 (d, $J = 11.8$ Hz, 1 H), 4.48 (d, $J = 12.0$ Hz, 1 H), 4.70 (m, 2 H), 4.85 (m, 2 H), 4.98 (t, $J = 9.8$ Hz, 1 H), 5.21 (t, $J = 9.8$ Hz, 1 H), 5.28 (m, 2 H), 6.97 (d, $J = 7.9$ Hz, 1 H), 7.17 (d, $J = 7.9$ Hz, 1 H), 7.29 (s, 1 H), 9.21 (s, 1 H). Anal. Calcd. for $\text{C}_{39}\text{H}_{53}\text{NO}_{19}$: C, 55.76; H, 6.36; N, 1.67. Found: C, 55.72; H, 6.39; N, 1.60.

15

EXAMPLE 13**N-[5-(Henta-O-acetyl- β -D-maltosyloxymethyl)-2-methylphenyll-2,2-dimethylpropionamide**

20

The title compound was prepared according to the procedure of Example 10 as a white foam; ^1H NMR ($\text{DMSO-}d_6$) δ 1.22 (s, 9 H), 1.93 (s, 3 H), 1.94 (s, 3 H), 1.95 (s, 3 H), 1.97 (s, 3 H), 1.98 (s, 3 H), 2.02 (s, 3 H), 2.09 (s, 3 H), 2.13 (s, 3 H), 3.97 (m, 4 H), 4.18 (m, 2 H), 4.39 (m, 1 H), 4.51 (d, $J = 12.0$ Hz, 1 H), 4.70 (m, 2
25 H), 4.84 (m, 2 H), 4.98 (t, $J = 9.8$ Hz, 1 H), 5.21 (t, $J = 9.8$ Hz, 1 H), 5.28 (m, 2 H), 7.02 (dd, $J = 7.9, 1.2$ Hz, 1 H), 7.09 (d, $J = 1.2$ Hz, 1 H), 7.19 (d, $J = 7.9$ Hz, 1 H), 8.88 (s, 1 H). Anal. Calcd. for $\text{C}_{39}\text{H}_{53}\text{NO}_{19}$: C, 55.76; H, 6.36; N, 1.67. Found: C, 55.53; H, 6.56; N, 1.61.

- 25 -

EXAMPLE 14**Cyclopropanecarboxylic Acid N-[5-(Henta-O-acetyl-β-D-maltosyloxymethyl)-2-methylphenyl]amide**

5

The title compound was prepared according to the procedure of Example 10 as a white foam; ¹H NMR (DMSO-*d*₆) δ 0.76 (d, J = 6.0 Hz, 4 H), 1.86 (m, 1 H), 1.92 (s, 3 H), 1.94 (s, 3 H), 1.96 (s, 6 H), 1.97 (s, 6 H), 2.01 (s, 3 H), 2.08 (s, 3 H), 2.18 (s, 3 H), 4.00 (m, 4 H), 4.21 (m, 2 H), 4.39 (dd, J = 12.0, 2.3 Hz, 1 H), 4.48 (d, J = 12.4 Hz, 1 H), 4.67 (d, J = 12.0 Hz, 1 H), 4.71 (t, J = 9.9 Hz, 1 H), 4.82 (d, J = 8.1 Hz, 1 H), 4.86 (dd, J = 10.6, 3.4 Hz, 1 H), 4.98 (t, J = 9.9 Hz, 1 H), 5.21 (t, J = 9.9 Hz, 1 H), 5.28 (m, 2 H), 6.96 (dd, J = 7.7, 1.4 Hz, 1 H), 7.17 (d, J = 7.7 Hz, 1 H), 7.28 (d, J = 1.4 Hz, 1 H), 9.16 (s, 1 H). Anal. Calcd. for C₃₈H₄₉NO₁₉: C, 55.40; H, 6.00; N, 1.70. Found: C, 55.25; H, 5.99; N, 1.68.

15

EXAMPLE 15**Cyclopentanecarboxylic Acid N-[5-(Henta-O-acetyl-β-D-maltosyloxymethyl)-2-methylphenyl]amide**

20

The title compound was prepared according to the procedure of Example 10 as a white foam; ¹H NMR (DMSO-*d*₆) δ 1.58 (m, 2 H), 1.71 (m, 4 H), 1.85 (m, 2 H), 1.92 (s, 3 H), 1.93 (s, 3 H), 1.94 (s, 3 H), 1.97 (s, 6 H), 2.01 (s, 3 H), 2.08 (s, 3 H), 2.15 (s, 3 H), 2.82 (m, 1 H), 4.00 (m, 4 H), 4.21 (m, 2 H), 4.39 (dd, J = 12.0, 2.3 Hz, 1 H), 4.48 (d, J = 9.9 Hz, 1 H), 4.82 (d, J = 8.1 Hz, 1 H), 4.86 (dd, J = 10.6, 3.9 Hz, 1 H), 4.98 (t, J = 9.9 Hz, 1 H), 5.21 (t, J = 9.9 Hz, 1 H), 5.28 (m, 2 H), 6.96 (dd, J = 7.7, 1.4 Hz, 1 H), 7.17 (d, J = 7.7 Hz, 1 H), 7.28 (d, J = 1.4 Hz, 1 H), 9.16 (s, 1 H). Anal. Calcd. for C₄₀H₅₃NO₁₉: C, 56.33; H, 5.72; N, 3.05. Found: C, 56.16; H, 5.79; N, 3.02.

30

EXAMPLE 16**N-[5-(Hepta-O-acetyl-β-D-maltosyloxymethyl)-2-methylphenyl]-3-cyclopentylpropionamide**

5

The title compound was prepared according to the procedure of Example 10 as a white foam; ¹H NMR (DMSO-*d*₆) δ 1.10 (m, 2 H), 1.48 (m, 2 H), 1.60 (m, 4 H), 1.78 (m, 2 H), 1.92 (s, 6 H), 1.94 (s, 3 H), 1.95 (m, 1 H), 1.98 (s, 6 H), 2.01 (s, 3 H), 2.10 (s, 3 H), 2.18 (s, 3 H), 2.32 (t, J = 7.7 Hz, 2 H), 4.00 (m, 4 H), 4.21 (m, 2 H), 4.39 (dd, J = 12.0, 2.3 Hz, 1 H), 4.48 (d, J = 12.4 Hz, 1 H), 4.67 (d, J = 12.0 Hz, 1 H), 4.71 (t, J = 9.9 Hz, 1 H), 5.28 (m, 2 H), 6.96 (dd, J = 7.7, 1.4 Hz, 1 H), 7.17 (d, J = 7.7 Hz, 1 H), 7.28 (d, J = 1.4 Hz, 1 H), 9.21 (s, 1 H). Anal. Calcd. for C₄₂H₅₇NO₁₉: C, 57.33; H, 6.53; N, 1.59. Found: C, 57.50; H, 6.52; N, 1.80.

15

EXAMPLE 17**N-[5-(Hepta-O-acetyl-β-D-maltosyloxymethyl)-2-methylphenyl]-4-(methanesulfonylamino)benzenesulfonamide**

20

To a mixture of 5-(hepta-O-acetyl-β-maltosyloxymethyl)-2-methylphenylamine (0.80 g, 1.06 mmol), prepared as described in Example 3, and pyridine (0.09 g, 1.06 mmol) in THF (10 mL) was added 4-(methanesulfonylamino)benzenesulfonyl chloride (0.29 g, 1.06 mmol). After 18 h, the mixture was diluted with EtOAc, washed with 5% aqueous KHSO₄, saturated aqueous NaHCO₃, and brine, dried (MgSO₄), and concentrated. Purification by flash chromatography (2% MeOH/CH₂Cl₂) gave a white foam and trituration with ether gave 0.80 g (83%) of product as a white solid, mp 116-118 °C; ¹H NMR (DMSO-*d*₆) δ 1.94 (s, 6 H), 1.97 (s, 12 H), 2.01 (s, 3 H), 2.09 (s, 3 H), 3.08 (s, 3 H), 4.01 (m, 4 H), 4.19 (m, 2 H), 4.37 (d, J = 12.2 Hz, 1 H), 4.41 (d, J = 12.2 Hz, 1 H), 4.70 (m, 2 H), 4.80 (d, J = 8.1 Hz, 1 H), 4.86 (dd, J = 10.6, 3.7 Hz, 1 H), 4.98 (t, J = 9.9 Hz, 1 H), 5.21 (t, J = 9.9 Hz, 1 H), 5.27 (t, J = 9.9 Hz, 1 H), 5.29 (d, J = 3.7 Hz, 1 H), 7.00 (dd, J = 7.9, 1.2 Hz, 1 H), 7.04 (d, J = 1.2 Hz, 1 H), 7.09 (d, J = 7.9 Hz, 1 H), 7.27 (d, J = 8.7 Hz, 2 H), 7.55 (d, J = 8.7 Hz, 2 H), 9.50 (s, 1 H), 10.35 (s, 1 H). Anal. Calcd. for C₄₁H₅₂N₂O₂₂S₂: C, 49.79; H, 5.30; N, 2.83. Found: C, 49.50; H, 5.28; N, 2.93.

35

EXAMPLE 18**N-[5-(Hepta-O-acetyl-β-D-maltosyloxymethyl)-2-methylphenyl]-4-cyanobenzenesulfonamide**

5

The title compound was prepared according to the procedure of Example 17 as a white foam; ¹H NMR (DMSO-*d*₆) δ 1.88 (s, 3 H), 1.93 (s, 3 H), 1.94 (s, 3 H), 1.95 (s, 3 H), 1.97 (s, 3 H), 1.98 (s, 3 H), 2.02 (s, 3 H), 2.09 (s, 3 H), 3.96 (m, 4 H), 4.35 (m, 2 H), 4.38 (d, J = 10.6 Hz, 1 H), 4.46 (d, J = 12.2 Hz, 1 H), 4.66 (m, 2 H), 4.81 (d, J = 7.9 Hz, 1 H), 4.86 (dd, J = 10.4, 3.7 Hz, 1 H), 4.98 (t, J = 9.8 Hz, 1 H), 5.22 (t, J = 10.4 Hz, 1 H), 5.29 (m, 2 H), 6.97 (d, J = 1.5 Hz, 1 H), 7.03 (dd, J = 7.9, 1.5 Hz, 1 H), 7.12 (d, J = 7.9 Hz, 1 H), 7.77 (d, J = 8.7 Hz, 2 H), 8.03 (d, J = 8.7 Hz, 2 H), 9.94 (s, 1 H). Anal. Calcd. for C₄₁H₄₈N₂O₂₀S: C, 53.48; H, 5.25; N, 3.04. Found: C, 53.08; H, 5.21; N, 2.89.

15

EXAMPLE 19**N-[5-(Hepta-O-acetyl-β-D-maltosyloxymethyl)-2-methylphenyl]-4-trifluoromethylbenzenesulfonamide**

20

The title compound was prepared according to the procedure of Example 17 as a white foam; ¹H NMR (DMSO-*d*₆) δ 1.86 (s, 3 H), 1.93 (s, 3 H), 1.94 (s, 3 H), 1.95 (s, 3 H), 1.97 (s, 3 H), 1.98 (s, 3 H), 2.02 (s, 3 H), 2.08 (s, 3 H), 3.95 (m, 4 H), 4.18 (m, 2 H), 4.38 (m, 1 H), 4.45 (d, J = 12.7 Hz, 1 H), 4.65 (m, 2 H), 4.80 (d, J = 7.9 Hz, 1 H), 4.86 (dd, J = 10.6, 3.9 Hz, 1 H), 4.98 (t, J = 9.8 Hz, 1 H), 5.21 (t, J = 9.8 Hz, 1 H), 5.28 (m, 2 H), 7.00 (s, 1 H), 7.03 (d, J = 7.9 Hz, 1 H), 7.12 (d, J = 7.9 Hz, 1 H), 7.83 (d, J = 8.1 Hz, 2 H), 7.95 (d, J = 8.1 Hz, 2 H), 9.90 (s, 1 H). Anal. Calcd. for C₄₁H₄₈F₃NO₂₀S: C, 51.09; H, 5.02; N, 1.45. Found: C, 50.87; H, 4.99; N, 1.50.

30

- 28 -

EXAMPLE 20**N-[5-(Henta-O-acetyl- β -D-maltosyloxymethyl)-2-methylphenyl]-3-trifluoromethylbenzenesulfonamide**

5

The title compound was prepared according to the procedure of Example 17 as a white foam; ^1H NMR ($\text{DMSO}-d_6$) δ 1.86 (s, 3 H), 1.93 (s, 3 H), 1.94 (s, 3 H), 1.95 (s, 3 H), 1.97 (s, 3 H), 1.98 (s, 3 H), 2.02 (s, 3 H), 2.08 (s, 3 H), 3.95 (m, 4 H), 4.18 (m, 2 H), 4.36 (m, 1 H), 4.44 (d, $J = 12.7$ Hz, 1 H), 4.64 (d, $J = 12.7$ Hz, 1 H), 4.69 (dd, $J = 9.5, 8.1$ Hz, 1 H), 4.79 (d, $J = 8.5$ Hz, 1 H), 4.86 (dd, $J = 10.6, 3.7$ Hz, 1 H), 4.98 (t, $J = 9.8$ Hz, 1 H), 5.22 (dd, $J = 10.4, 9.5$ Hz, 1 H), 5.28 (m, 2 H), 6.96 (d, $J = 1.5$ Hz, 1 H), 7.04 (dd, $J = 8.1, 1.5$ Hz, 1 H), 7.12 (d, $J = 8.1$ Hz, 1 H), 7.81 (m, 1 H), 7.86 (s, 1 H), 7.90 (d, $J = 8.5$ Hz, 1 H), 8.05 (d, $J = 7.9$ Hz, 1 H), 9.86 (s, 1 H). Anal. Calcd. for $\text{C}_{41}\text{H}_{48}\text{F}_3\text{NO}_{20}\text{S}$: C, 51.09; H, 5.02; N, 1.45. Found: C, 50.87; H, 4.97; N, 1.46.

15

EXAMPLE 21**N-[5-(Henta-O-acetyl- β -D-maltosyloxymethyl)-2-methylphenyl]-3-trifluoromethylbenzenesulfonamide**

20

The title compound was prepared according to the procedure of Example 17 as a white foam; ^1H NMR ($\text{DMSO}-d_6$) δ 1.90 (s, 3 H), 1.92 (s, 3 H), 1.93 (s, 3 H), 1.94 (s, 3 H), 1.98 (s, 6 H), 2.02 (s, 3 H), 2.08 (s, 3 H), 3.95 (m, 4 H), 4.18 (m, 2 H), 4.38 (m, 1 H), 4.44 (d, $J = 12.2$ Hz, 1 H), 4.63 (d, $J = 12.2$ Hz, 1 H), 4.69 (dd, $J = 9.5, 8.1$ Hz, 1 H), 4.77 (d, $J = 8.1$ Hz, 1 H), 4.86 (dd, $J = 10.6, 3.9$ Hz, 1 H), 4.98 (t, $J = 9.5$ Hz, 1 H), 5.22 (dd, $J = 10.4, 9.8$ Hz, 1 H), 5.28 (m, 2 H), 7.02 (m, 2 H), 7.11 (d, $J = 7.9$ Hz, 1 H), 7.80 (m, 3 H), 7.99 (d, $J = 7.5$ Hz, 1 H), 9.79 (s, 1 H). Anal. Calcd. for $\text{C}_{41}\text{H}_{48}\text{F}_3\text{NO}_{20}\text{S}$: C, 51.09; H, 5.02; N, 1.45. Found: C, 50.85; H, 4.89; N, 1.45.

25
30

EXAMPLE 22**N-[5-(Hepta-O-acetyl-β-D-maltosyloxymethyl)-2-methylphenyl]-3-(methanesulfonylamino)benzenesulfonamide**

5

The title compound was prepared according to the procedure of Example 17 as a white solid, mp 122-124 °C; ¹H NMR (DMSO-*d*₆) δ 1.84 (s, 3 H), 1.93 (s, 3 H), 1.94 (s, 6 H), 2.01 (s, 3 H), 2.09 (s, 3 H), 2.93 (s, 3 H), 4.00 (m, 4 H), 4.20 (m, 2 H), 4.40 (d, J = 12.0 Hz, 1 H), 4.43 (d, J = 12.4 Hz, 1 H), 4.70 (m, 2 H), 4.79 (d, J = 7.9 Hz, 1 H), 4.86 (dd, J = 10.6, 3.9 Hz, 1 H), 4.97 (t, J = 9.9 Hz, 1 H), 5.21 (t, J = 9.9 Hz, 1 H), 5.27 (d, J = 3.9 Hz, 1 H), 5.29 (t, J = 9.9 Hz, 1 H), 7.01 (d, J = 7.7 Hz, 1 H), 7.02 (s, 1 H), 7.09 (d, J = 7.7 Hz, 1 H), 7.28 (dd, J = 7.9, 1.9 Hz, 1 H), 7.40 (dd, J = 7.9, 1.9 Hz, 1 H), 7.47 (m, 1 H), 7.53 (m, 1 H), 9.66 (s, 1 H), 10.11 (s, 1 H). Anal. Calcd. for C₄₁H₅₂N₂O₂₂S₂: C, 49.79; H, 5.30; N, 2.83. Found: C, 49.36; H, 5.31; N, 2.95.

15

EXAMPLE 23**N-[5-(Hepta-O-acetyl-β-D-maltosyloxymethyl)-2-methylphenyl]-4-methoxybenzenesulfonamide**

20

The title compound was prepared according to the procedure of Example 17 as a white foam; ¹H NMR (DMSO-*d*₆) δ 1.90 (s, 3 H), 1.93 (s, 3 H), 1.94 (s, 3 H), 1.95 (s, 3 H), 1.98 (s, 3 H), 2.02 (s, 3 H), 2.09 (s, 3 H), 3.81 (s, 3 H), 3.96 (m, 4 H), 4.18 (m, 2 H), 4.38 (m, 1 H), 4.44 (d, J = 12.5 Hz, 1 H), 4.63 (d, J = 12.5 Hz, 1 H), 4.70 (dd, J = 9.3, 8.1 Hz, 1 H), 4.77 (d, J = 7.9 Hz, 1 H), 4.86 (dd, J = 10.6, 3.9 Hz, 1 H), 4.98 (t, J = 9.8 Hz, 1 H), 5.22 (dd, J = 10.4, 9.8 Hz, 1 H), 5.28 (m, 2 H), 7.03 (m, 5 H), 7.55 (d, J = 9.1 Hz, 1 H), 9.41 (s, 1 H). Anal. Calcd. for C₄₁H₅₁NO₂₁S: C, 53.19; H, 5.55; N, 1.51. Found: C, 52.80; H, 5.41; N, 1.52.

30

EXAMPLE 24**N-[5-(Hepta-O-acetyl-β-D-maltosyloxymethyl)-2-methylphenyl]-4-methylbenzenesulfonamide**

5

The title compound was prepared according to the procedure of Example 17 as a white foam; ¹H NMR (DMSO-*d*₆) δ 1.87 (s, 3 H), 1.94 (s, 6 H), 1.95 (s, 3 H), 1.98 (s, 6 H), 2.02 (s, 3 H), 2.09 (s, 3 H), 2.36 (s, 3 H), 3.95 (m, 4 H), 4.17 (m, 2 H), 4.38 (dd, J = 11.8, 1.0 Hz, 1 H), 4.43 (d, J = 12.2 Hz, 1 H), 4.64 (d, J = 12.2 Hz, 1 H), 4.70 (dd, J = 9.3, 8.1 Hz, 1 H), 4.77 (d, J = 8.1 Hz, 1 H), 4.86 (dd, J = 10.4, 3.7 Hz, 1 H), 4.98 (t, J = 9.8 Hz, 1 H), 5.22 (t, J = 10.1 Hz, 1 H), 5.28 (m, 2 H), 6.98 (d, J = 8.1 Hz, 1 H), 7.03 (s, 1 H), 7.08 (d, J = 8.1 Hz, 1 H), 7.33 (d, J = 8.1 Hz, 2 H), 7.51 (d, J = 8.1 Hz, 2 H), 9.49 (s, 1 H). Anal. Calcd. for C₄₁H₅₁NO₂₀S: C, 54.12; H, 5.65; N, 1.54. Found: C, 53.79; H, 5.53; N, 1.53.

15

EXAMPLE 25**N-[5-(Hepta-O-acetyl-β-D-maltosyloxymethyl)-2-methylphenyl]-4-chlorobenzenesulfonamide**

20

The title compound was prepared according to the procedure of Example 17 as a white foam; ¹H NMR (DMSO-*d*₆) δ 1.89 (s, 3 H), 1.94 (s, 6 H), 1.95 (s, 3 H), 1.98 (s, 6 H), 2.02 (s, 3 H), 2.09 (s, 3 H), 3.99 (m, 4 H), 4.16 (dd, J = 12.0, 4.4 Hz, 1 H), 4.20 (m, 1 H), 4.39 (dd, J = 11.4, 0.6 Hz, 1 H), 4.45 (d, J = 12.2 Hz, 1 H), 4.65 (d, J = 12.2 Hz, 1 H), 4.71 (dd, J = 9.3, 7.9 Hz, 1 H), 4.79 (d, J = 7.9 Hz, 1 H), 4.86 (dd, J = 10.4, 3.7 Hz, 1 H), 4.98 (t, J = 9.8 Hz, 1 H), 5.22 (dd, J = 10.2, 9.5 Hz, 1 H), 5.28 (m, 2 H), 7.01 (m, 2 H), 7.11 (d, J = 7.7 Hz, 1 H), 7.62 (s, 4 H), 9.72 (s, 1 H). Anal. Calcd. for C₄₀H₄₈ClNO₂₀S: C, 51.64; H, 5.20; N, 1.51. Found: C, 51.47; H, 5.10; N, 1.58.

30

EXAMPLE 26**N-[5-(Hepta-O-acetyl- β -D-maltosyloxymethyl)-2-methylphenyl]-4-chloro-3-nitrobenzenesulfonamide**

5

The title compound was prepared according to the procedure of Example 17 as a white foam; ^1H NMR ($\text{DMSO}-d_6$) δ 1.92 (s, 3 H), 1.93 (s, 3 H), 1.94 (s, 3 H), 1.97 (s, 6 H), 1.98 (s, 3 H), 2.01 (s, 3 H), 2.07 (s, 3 H), 4.00 (m, 4 H), 4.20 (m, 2 H), 4.39 (dd, $J = 12.0, 2.3$ Hz, 1 H), 4.46 (d, $J = 12.0$ Hz, 1 H), 4.68 (m, 2 H), 4.80 (d, $J = 8.1$ Hz, 1 H), 4.85 (dd, $J = 10.6, 3.7$ Hz, 1 H), 4.98 (t, $J = 9.9$ Hz, 1 H), 5.22 (t, $J = 9.9$ Hz, 1 H), 5.28 (d, $J = 3.7$ Hz, 1 H), 5.30 (m, 1 H), 6.94 (d, $J = 1.5$ Hz, 1 H), 7.07 (dd, $J = 7.7, 1.5$ Hz, 1 H), 7.17 (d, $J = 7.7$ Hz, 1 H), 7.86 (dd, $J = 8.5, 2.1$ Hz, 1 H), 7.96 (d, $J = 8.5$ Hz, 1 H), 8.29 (d, $J = 2.1$ Hz, 1 H), 10.02 (s, 1 H). Anal. Calcd. for $\text{C}_{40}\text{H}_{47}\text{ClN}_2\text{O}_{22}\text{S}$: C, 49.26; H, 4.86; N, 2.87. Found: C, 49.19; H, 4.71; N, 2.62.

15

EXAMPLE 27**N-[5-(Hepta-O-acetyl- β -D-maltosyloxymethyl)-2-methylphenyl]methanesulfonamide**

20

The title compound was prepared according to the procedure of Example 17 as a white solid, mp 96-98 $^{\circ}\text{C}$; ^1H NMR ($\text{DMSO}-d_6$) δ 1.93 (s, 6 H), 1.94 (s, 3 H), 1.97 (s, 6 H), 2.01 (s, 3 H), 2.08 (s, 3 H), 2.28 (s, 3 H), 2.96 (s, 3 H), 3.98 (m, 4 H), 4.19 (m, 2 H), 4.40 (dd, $J = 12.0, 2.3$ Hz, 1 H), 4.71 (m, 2 H), 4.85 (m, 2 H), 4.97 (t, $J = 9.9$ Hz, 1 H), 5.21 (t, $J = 9.9$ Hz, 1 H), 5.27 (d, $J = 3.7$ Hz, 1 H), 5.29 (t, $J = 9.9$ Hz, 1 H), 7.05 (dd, $J = 7.7, 1.2$ Hz, 1 H), 7.19 (d, $J = 1.2$ Hz, 1 H), 7.22 (d, $J = 7.7$ Hz, 1 H), 9.05 (s, 1 H). Anal. Calcd. for $\text{C}_{35}\text{H}_{47}\text{NO}_{20}\text{S}$: C, 50.42; H, 5.68; N, 1.68. Found: C, 50.29; H, 5.56; N, 1.58.

30

EXAMPLE 28**Butane-1-sulfonic Acid N-[5-(Henta-O-acetyl- β -D-maltosyloxymethyl)-2-methylphenyl]amide**

5

The title compound was prepared according to the procedure of Example 17 as a white foam; ^1H NMR ($\text{DMSO}-d_6$) δ 0.87 (t, $J = 7.5$ Hz, 3 H), 1.39 (m, 2 H), 1.68 (m, 2 H), 1.93 (s, 3 H), 1.94 (s, 3 H), 1.95 (s, 3 H), 1.97 (s, 6 H), 1.98 (s, 3 H), 2.02 (s, 3 H), 2.09 (s, 3 H), 2.28 (s, 3 H), 3.05 (dd, $J = 7.7, 6.6$ Hz, 2 H), 3.95 (m, 4 H), 4.18 (m, 2 H), 4.40 (dd, $J = 11.8, 1.2$ Hz, 1 H), 4.51 (d, $J = 12.2$ Hz, 1 H), 4.71 (m, 2 H), 4.85 (m, 2 H), 4.98 (t, $J = 9.8$ Hz, 1 H), 5.21 (t, $J = 9.8$ Hz, 1 H), 5.29 (m, 2 H), 7.03 (d, $J = 7.7$ Hz, 1 H), 7.18 (s, 1 H), 7.21 (d, $J = 7.7$ Hz, 1 H), 9.04 (s, 1 H). Anal. Calcd. for $\text{C}_{38}\text{H}_{51}\text{NO}_{20}\text{S}$: C, 52.23; H, 5.88; N, 1.60. Found: C, 51.88; H, 5.97; N, 1.52.

15

EXAMPLE 29**4-(Henta-O-acetyl- β -D-maltosyloxymethyl)-2-methylphenylamine**20 **Step 1****4-(Henta-O-acetyl- β -maltosyloxymethyl)-2-methyl-1-nitrobenzene**

A mixture of 3-methyl-4-nitrobenzyl alcohol (5.0 g, 0.030 mol), acetobromo- α -maltose (25.1 g, 0.036 mol), $\text{Hg}(\text{CN})_2$ (9.2 g, 0.036 mol), and HgBr_2 (5.4 g, 0.015 mol) in THF (130 mL) was stirred at room temperature for 48 h. Saturated aqueous NaCl (100 mL) was added and the mixture was stirred for 20 min. The reaction mixture was extracted with EtOAc and the organic phase was washed with saturated aqueous NaHCO_3 and saturated aqueous NaCl, dried (MgSO_4), and concentrated to give a yellow foam. Trituration with ether gave 6.9 g (30%) of product as a white solid, mp 138-140 $^\circ\text{C}$; ^1H NMR ($\text{DMSO}-d_6$) δ 1.92 (s, 6 H), 1.95 (s, 6 H), 1.99 (s, 6 H), 2.05 (s, 3 H), 2.48 (s, 3 H), 3.96 (m, 4 H), 4.15 (m, 2 H), 4.37 (d, $J = 11.7$ Hz, 1 H), 4.81 (m, 6 H), 5.25 (m, 3 H), 7.30 (d, $J = 8.3$ Hz, 1 H), 7.33 (s, 1 H), 7.98 (d, $J = 8.3$ Hz, 1 H).

30

- 33 -

Step 2**4-(Hepta-O-acetyl- β -maltosyloxymethyl)-2-methylphenylamine**

A solution of 4-(hepta-O-acetyl- β -maltosyl-oxymethyl)-2-methyl-1-nitrobenzene (5.95 g, 7.57 mmol) in EtOAc (80 mL) was hydrogenated at 50 psi over 10% Pd/C (2.60 g) for 30 min. The catalyst was removed by filtration and the filtrate was concentrated to give a white foam. Trituration with 40% EtOAc/hexane gave 5.70 g (100%) of product as a white solid, mp 164 - 166 °C; ^1H NMR (DMSO- d_6) δ 1.92 (s, 3 H), 1.94 (s, 3 H), 1.97 (s, 6 H), 1.99 (s, 6 H), 2.01 (s, 3 H), 2.07 (s, 3 H), 3.98 (m, 4 H), 4.17 (m, 2 H), 4.30 (d, J = 12.0 Hz, 1 H), 4.37 (d, J = 12.0 Hz, 1 H), 4.50 (d, J = 12.0 Hz, 1 H), 4.62 (d, J = 10.6 Hz, 1 H), 4.75 (d, J = 8.1 Hz, 1 H), 4.82 (m, 2 H), 4.97 (t, J = 9.9 Hz, 1 H), 5.25 (m, 4 H), 6.58 (d, J = 8.3 Hz, 1 H), 6.78 (d, J = 8.3 Hz, 1 H), 6.81 (s, 1 H).

A hydrochloride salt was prepared by treating a solution of free base (0.50 g, 0.66 mmol) in dioxane (1.5 mL) with saturated ethereal HCl (25 mL). The precipitate was collected by filtration to give 0.35 g (67%) of the title compound as a white solid, hydrochloride salt, mp 160 °C (dec). Anal. Calcd. for $\text{C}_{34}\text{H}_{46}\text{NO}_{18}\cdot\text{HCl}$: C, 51.55; H, 5.85; N, 1.77. Found: C, 50.92; H, 5.54; N, 1.84.

EXAMPLE 30**N-[4-(Hepta-O-acetyl- β -D-maltosyloxymethyl)-2-methylphenyl]-4-(methanesulfonylamino)benzenesulfonamide**

To a cooled (0 °C) solution of 4-(hepta-O-acetyl- β -maltosyloxymethyl)-2-methylphenylamine (0.80 g, 1.06 mmol), prepared as described in Example 29, and Et_3N (0.11 g, 1.11 mmol) in THF (8 mL) was added 4-(methylsulfonylamino)benzenesulfonyl chloride (0.30 g, 1.11 mmol). The cooling bath was removed and stirring was continued for 24 h at room temperature. EtOAc was added and the mixture was washed with water and brine, dried (MgSO_4), and concentrated. Purification by flash chromatography (40% EtOAc/hexane) gave 0.50 g (48%) of product as a white solid, mp 116-118 °C; ^1H NMR (DMSO- d_6) δ 1.88 (s, 3 H), 1.92 (s, 3 H), 1.94 (s, 3 H), 1.97 (s, 9 H), 2.01 (s, 3 H), 2.07 (s, 3 H), 3.10 (s, 3 H), 3.98 (m, 4 H), 4.19 (m, 2 H), 4.37 (dd, J = 12.0, 2.3 Hz, 1 H), 4.48 (d, J =

- 34 -

12.4 Hz, 1 H), 4.82 (d, J = 8.1 Hz, 1 H), 4.87 (dd, J = 10.6, 3.9 Hz, 1 H), 4.98 (t, J = 9.9 Hz, 1 H), 5.21 (t, J = 9.9 Hz, 1 H), 5.25 (d, J = 3.7 Hz, 1 H), 5.28 (t, J = 9.9 Hz, 1 H), 6.93 (d, J = 8.1 Hz, 1 H), 6.98 (dd, J = 8.1, 1.4 Hz, 1 H), 7.03 (d, J = 1.4 Hz, 1 H), 7.28 (d, J = 8.9 Hz, 2 H), 7.61 (d, J = 8.9 Hz, 2 H), 9.48 (s, 1 H), 10.36 (s, 1 H). Anal. Calcd. for $C_{41}H_{52}N_2O_{22}S_2$: C, 49.79; H, 5.30; N, 2.83. Found: C, 49.66; H, 5.44; N, 2.86.

EXAMPLE 31

10 N-[4-(Hepta-O-acetyl-β-D-maltosyloxymethyl)-2-methylphenyl]-4-nitro-N-(4-nitrophenylsulfonyl)benzenesulfonamide

The title compound was prepared according to the procedure of Example 30, Step 3 but di-4-nitrobenzenesulfonation occurred to give the product as a yellow solid, mp 126-128 °C; 1H NMR (DMSO- d_6) δ 1.90 (s, 3 H), 1.94 (s, 3 H), 1.95 (s, 3 H), 1.97 (s, 3 H), 1.98 (s, 3 H), 2.02 (s, 3 H), 2.07 (s, 3 H), 2.08 (s, 3 H), 4.00 (m, 4 H), 4.20 (m, 2 H), 4.39 (dd, J = 12.0, 2.3 Hz, 1 H), 4.67 (d, J = 12.0 Hz, 1 H), 4.78 (m, 2 H), 4.85 (dd, J = 10.6, 3.9 Hz, 1 H), 4.95 (d, J = 8.1 Hz, 1 H), 5.01 (d, J = 9.9 Hz, 1 H), 5.21 (t, J = 9.9 Hz, 1 H), 5.30 (d, J = 3.7 Hz, 1 H), 5.38 (t, J = 9.9 Hz, 1 H), 6.95 (d, J = 8.1 Hz, 1 H), 7.18 (dd, J = 8.1, 1.4 Hz, 1 H), 7.28 (d, J = 1.4 Hz, 1 H), 8.08 (d, J = 8.9 Hz, 4 H), 8.52 (d, J = 8.9 Hz, 4 H). Anal. Calcd. for $C_{46}H_{51}N_3O_{26}S_2$: C, 49.07; H, 4.57; N, 3.73. Found: C, 48.77; H, 4.59; N, 3.56.

- 35 -

EXAMPLE 32

N-Acetyl-4-[acetyl(methanesulfonyl)amino]-N-[5-(4',6'-O-isopropylidene-2,2',3,3',6-penta-O-acetyl- β -D-maltosyloxymethyl)-2-methylphenyl]benzenesulfonamide

Step 1

N-[5-(β -D-Maltosyloxymethyl)-2-methylphenyl]-4-(methanesulfonylamino)benzenesulfonamide

A mixture of N-[5-(hepta-O-acetyl- β -D-maltosyloxymethyl)-2-methylphenyl]-4-(methanesulfonylamino)benzenesulfonamide (2.08 g, 2.10 mmol), prepared as described in Example 17, and 25 weight% NaOMe in MeOH (4.82 mL, 21.0 mmol) in MeOH (20 mL) was stirred at room temperature for 2 h. Amberlite IR-120(H⁺) was added until a pH of 5-6 resulted. The mixture was filtered and the filtrate was concentrated to give 1.50 g (98%) of product as an off-white foam. The material was used directly in the next reaction without further purification.

Step 2

N-Acetyl-4-[acetyl(methanesulfonyl)amino]-N-[5-(4',6'-O-isopropylidene-2,2',3,3',6-penta-O-acetyl- β -D-maltosyloxymethyl)-2-methylphenyl]benzenesulfonamide

To a suspension of N-[5-(β -D-maltosyloxymethyl)-2-methylphenyl]-4-(methanesulfonylamino)benzenesulfonamide (0.79 g, 1.14 mmol) in CH₃CN (20 mL) was added dimethoxypropane (0.36 g, 3.41 mmol) and camphorsulfonic acid (13 mg, 0.06 mmol). After 6 h, the mixture was concentrated, taken up in CH₃CN (20 mL), and dimethoxypropane (0.85 g, 8.13 mmol) was added. After 2.5 days, saturated aqueous NaHCO₃ (3 mL) was added and the mixture was filtered. The filtrate was concentrated, taken up in acetone, passed through a short plug of silica gel, and concentrated to give 0.83 g (100%) of N-[5-(4',6'-O-isopropylidene- β -D-maltosyloxymethyl)-2-methylphenyl]-4-(methanesulfonylamino)benzenesulfonamide as a brown foam. This material was used directly in the next reaction without further purification.

- 36 -

To a cooled (0°C) solution of N-[5-(4',6'-O-isopropylidene-β-D-maltosyloxy-methyl)-2-methylphenyl]-4-(methanesulfonylamino)benzenesulfonamide (0.83 g, 1.14 mmol) in pyridine (2.3 mL) was added acetic anhydride (2.2 mL). The cooling bath was removed and stirring was continued at room temperature for 2 days. The mixture was recooled (0 °C) and ice was added. After 30 min, the mixture was concentrated, taken up in EtOAc, washed with 0.5 N HCl, water, and saturated aqueous NaHCO₃, dried (MgSO₄), and concentrated. Purification by flash chromatography (60% EtOAc/hexane) and trituration with ether gave 0.52 g (44%) of product as an off-white solid, mp 159-163 °C; mass spectrum *m/z* [M+H]⁺ 1029. Anal. Calcd. for C₄₄H₅₆N₂O₂₂S₂: C, 51.36; H, 5.49; N, 2.72. Found: C, 51.10; H, 5.53; N, 2.72.

EXAMPLE 33


N-Propionyl-4-[propionyl(methanesulfonyl)amino]-N-[5-(hepta-O-propionyl-β-D-maltosyloxymethyl)-2-methylphenyl]benzenesulfonamide

A mixture of N-[5-(β-D-maltosyloxymethyl)-2-methylphenyl]-4-(methanesulfonylamino)benzenesulfonamide (0.195 g, 0.281 mmol), prepared according to Example 32, Step 1, pyridine (0.90 g, 11.23 mmol), and propionic anhydride (1.50 g, 11.23 mmol) was stirred at room temperature for 3 days. The mixture was concentrated, diluted with EtOAc, washed with water, 10% KHSO₄, saturated aqueous NaHCO₃, and brine, dried (MgSO₄), and concentrated to give a yellow foam. Trituration with hexane gave 0.11 g (33%) of product as a white solid, mp 98-100 °C; ¹H NMR (DMSO-*d*₆) δ 1.00 (m, 21 H), 2.20 (m, 17 H), 3.60 (s, 3 H), 4.00 (m, 4 H), 4.20 (m, 2 H), 4.40 (m, 1 H), 4.62 (m, 1 H), 4.80 (m, 2 H), 4.88 (dd, J = 12.0, 2.3 Hz, 1 H), 4.97 (t, J = 9.9 Hz, 1 H), 5.02 (t, J = 9.9 Hz, 1 H), 5.26 (m, 2 H), 5.36 (m, 1 H), 7.21 (m, 1 H), 7.34 (m, 1 H), 7.45 (m, 1 H), 7.80 (m, 2 H), 8.13 (m, 2 H). Anal. Calcd. for C₅₄H₇₄N₂O₂₄S₂: C, 54.09; H, 6.22; N, 2.34. Found: C, 53.93; H, 6.11; N, 2.40.


- 37 -

We claim:

1. A compound of the general formula I



- 5 where X is



R^1 is H, alkyl having 1 to 6 carbon atoms, halo, CF_3 , CN, NO_2 , or alkoxy having 1 to 6 carbon atoms;

- 10 R^2 is H, an acyl group having 1 to 6 carbon atoms, phenylsulfonyl, or phenylsulfonyl; and

R^3 is an acyl group having 1 to 8 carbon atoms, benzoyl, substituted benzoyl, alkylsulfonyl having 1 to 6 carbon atoms, phenyl sulphonyl or substituted phenyl sulphonyl,


- 15 R^4 , R^5 , R^6 , R^7 , R^8 , and R^9 are each, independently, an acyl group having 1 to 6 carbon atoms; and

R^{10} and R^{11} are each, independently, an acyl group having 1 to 6 carbon atoms, or the R^{10} and R^{11} groups on the 4' and 6' positions of the maltose or the 4 and 6 positions of the glucose form an isopropylidene group;


or a pharmaceutically acceptable salt thereof.

- 38 -

2. A compound according to claim 1 of formula I



where X is



- 5 R^1 is H or alkyl having 1 to 6 carbon atoms;

R^2 is H, an acyl group having 1 to 6 carbon atoms, phenylsulfonyl, or 4-nitrophenylsulfonyl; and

- 10 R^3 is an acyl group having 1 to 8 carbon atoms, benzoyl, benzoyl substituted with nitro, amino, acetamido, 3,5-di-tert-butyl-4-hydroxybenzamido, cyano, or carbomethoxy group, alkylsulfonyl having 1 to 6 carbon atoms, phenylsulfonyl, or phenylsulfonyl substituted with methanesulfonylamino, cyano, trifluoromethyl, alkoxy having 1 to 6 carbon atoms, alkyl having 1 to 6 carbon atoms, chloro, or nitro group.

$\text{R}^4, \text{R}^5, \text{R}^6, \text{R}^7, \text{R}^8$, and R^9 are each, independently, an acyl group having 1 to 6 carbon atoms; and

- 15 R^{10} and R^{11} are each, independently, an acyl group having 1 to 6 carbon atoms, or the R^2 groups on the 4' and 6' positions of the maltose or the 4 and 6 positions of the glucose form an isopropylidene group;

or a pharmaceutically acceptable salt thereof.

- 39 -

3. A compound of Claim 1 which is N-[2-methyl-5-(2,3,4,6-tetra-O-acetyl- β -D-glucopyranosyloxymethyl)phenyl]-3-nitrobenzamide or a pharmaceutically acceptable salt thereof.

5 4. A compound of Claim 1 which is 3-amino-N-[2-methyl-5-(2,3,4,6-tetra-O-acetyl- β -D-glucopyranosyloxymethyl)phenyl]benzamide or a hydrate or a pharmaceutically acceptable salt thereof.

5. A compound of Claim 1 which is 5-(hepta-O-acetyl- β -maltosyloxymethyl)-2-methylphenylamine or a pharmaceutically acceptable salt thereof.

10 6. A compound of Claim 1 which is N-[5-(hepta-O-acetyl- β -D-maltosyloxymethyl)-2-methylphenyl]-3-nitrobenzamide or a pharmaceutically acceptable salt thereof.

7. A compound of Claim 1 which is N-[5-(hepta-O-acetyl- β -D-maltosyloxymethyl)-2-methylphenyl]-3-aminobenzamide or a pharmaceutically acceptable salt thereof.

15 8. A compound of Claim 1 which is 3-acetylamino-N-[5-(hepta-O-acetyl- β -D-maltosyloxymethyl)-2-methylphenyl]benzamide or a pharmaceutically acceptable salt thereof.

20 9. A compound of Claim 1 which is N-[3-[2-(hepta-O-acetyl- β -D-maltosyloxymethyl)-6-methylphenylcarbonyl]phenyl]-3,5-di-tert-butyl-4-hydroxybenzamide or a pharmaceutically acceptable salt thereof.

10. A compound of Claim 1 which is N-[5-(hepta-O-acetyl- β -D-maltosyloxymethyl)-2-methylphenyl]-3-cyanobenzamide or a pharmaceutically acceptable salt thereof.

25 11. A compound of Claim 1 which is N-[5-(hepta-O-acetyl- β -D-maltosyloxymethyl)-2-methylphenyl]-5-nitroisophthalamide or a pharmaceutically acceptable salt thereof.

12. A compound of Claim 1 which is N-[5-(hepta-O-acetyl- β -D-maltosyloxymethyl)-2-methylphenyl]acetamide or a pharmaceutically acceptable salt thereof.

- 40 -

13. A compound of Claim 1 which is N-[5-(hepta-O-acetyl- β -D-maltosyloxymethyl)-2-methylphenyl]propionamide or a pharmaceutically acceptable salt thereof.
- 5 14. A compound of Claim 1 which is pentanoic acid N-[5-(Hepta-O-acetyl- β -D-maltosyloxymethyl)-2-methylphenyl]amide or a pharmaceutically acceptable salt thereof.
15. A compound of Claim 1 which is N-[5-(hepta-O-acetyl- β -D-maltosyloxymethyl)-2-methylphenyl]-2,2-dimethylpropionamide or a pharmaceutically acceptable salt thereof.
- 10 16. A compound of Claim 1 which is cyclopropanecarboxylic acid N-[5-(hepta-O-acetyl- β -D-maltosyloxymethyl)-2-methylphenyl]amide or a pharmaceutically acceptable salt thereof.
- 15 17. A compound of Claim 1 which is cyclopentanecarboxylic acid N-[5-(hepta-O-acetyl- β -D-maltosyloxymethyl)-2-methylphenyl]amide or a pharmaceutically acceptable salt thereof.
18. A compound of Claim 1 which is N-[5-(hepta-O-acetyl- β -D-maltosyloxymethyl)-2-methylphenyl]-3-cyclopentylpropionamide or a pharmaceutically acceptable salt thereof.
- 20 19. A compound of Claim 1 which is N-[5-(hepta-O-acetyl- β -D-maltosyloxymethyl)-2-methylphenyl]-4-(methanesulfonylamino)benzenesulfonamide or a pharmaceutically acceptable salt thereof.
20. A compound of Claim 1 which is N-[5-(hepta-O-acetyl- β -D-maltosyloxymethyl)-2-methylphenyl]-4-cyanobenzenesulfonamide or a pharmaceutically acceptable salt thereof.
- 25 21. A compound of Claim 1 which is N-[5-(hepta-O-acetyl- β -D-maltosyloxymethyl)-2-methylphenyl]-4-trifluoromethylbenzenesulfonamide or a pharmaceutically acceptable salt thereof.

22. A compound of Claim 1 which is N-[5-(hepta-O-acetyl- β -D-maltosyloxymethyl)-2-methylphenyl]-3-trifluoromethylbenzenesulfonamide or a pharmaceutically acceptable salt thereof.

5 23. A compound of Claim 1 which is N-[5-(hepta-O-acetyl- β -D-maltosyloxymethyl)-2-methylphenyl]-2-trifluoromethylbenzenesulfonamide or a pharmaceutically acceptable salt thereof.

24. A compound of Claim 1 which is N-[5-(hepta-O-acetyl- β -D-maltosyloxymethyl)-2-methylphenyl]-3-(methanesulfonylamino)benzenesulfonamide or a pharmaceutically acceptable salt thereof.

10 25. A compound of Claim 1 which is N-[5-(hepta-O-acetyl- β -D-maltosyloxymethyl)-2-methylphenyl]-4-methoxybenzenesulfonamide or a pharmaceutically acceptable salt thereof.

15 26. A compound of Claim 1 which is N-[5-(hepta-O-acetyl- β -D-maltosyloxymethyl)-2-methylphenyl]-4-methylbenzenesulfonamide or a pharmaceutically acceptable salt thereof.

27. A compound of Claim 1 which is N-[5-(hepta-O-acetyl- β -D-maltosyloxymethyl)-2-methylphenyl]-4-chlorobenzenesulfonamide or a pharmaceutically acceptable salt thereof.

20 28. A compound of Claim 1 which is N-[5-(hepta-O-acetyl- β -D-maltosyloxymethyl)-2-methylphenyl]-4-chloro-3-nitrobenzenesulfonamide or a pharmaceutically acceptable salt thereof.

29. A compound of Claim 1 which is N-[5-(hepta-O-acetyl- β -D-maltosyloxymethyl)-2-methylphenyl]methanesulfonamide or a pharmaceutically acceptable salt thereof.

25 30. A compound of Claim 1 which is butane-1-sulfonic acid N-[5-(hepta-O-acetyl- β -D-maltosyloxymethyl)-2-methylphenyl]amide or a pharmaceutically acceptable salt thereof.

31. A compound of Claim 1 which is 4-(hepta-O-acetyl- β -D-maltosyloxy-methyl)-2-methylphenylamine or a pharmaceutically acceptable salt thereof.


32. A compound of Claim 1 which is N-[4-(hepta-O-acetyl- β -D-maltosyloxymethyl)-2-methylphenyl]-4-(methanesulfonylamino)benzenesulfonamide
5 or a pharmaceutically acceptable salt thereof.

33. A compound of Claim 1 which is N-[4-(hepta-O-acetyl- β -D-maltosyloxymethyl)-2-methylphenyl]-4-nitro-N-(4-nitrophenylsulfonyl)benzenesulfonamide or a pharmaceutically acceptable salt thereof.


34. A compound of Claim 1 which is N-acetyl-4-[acetyl(methanesulfonyl)-amino]-N-[5-(4',6'-O-isopropylidene-2,2',3,3',6-penta-O-acetyl- β -D-maltosyloxy-methyl)-2-methylphenyl]benzenesulfonamide or a pharmaceutically acceptable salt
10 thereof.

35. A compound of Claim 1 which is N-propionyl-4-[propionyl(methanesulfonyl)amino]-N-[5-(hepta-O-propionyl- β -D-maltosyloxymethyl)-2-methylphenyl]-benzenesulfonamide or a pharmaceutically acceptable salt thereof.
15

36. A method of treating a human suffering from a condition which is characterized by excessive smooth muscle proliferation, the method comprising administering to the human an effective amount of a compound of formula I



20 where X is



- 43 -

R^1 is H, alkyl having 1 to 6 carbon atoms, chloro, bromo, or alkoxy having 1 to 6 carbon atoms;

R^2 is H, an acyl group having 1 to 6 carbon atoms, phenylsulfonyl, or substituted phenylsulfonyl; and

5 R^3 is an acyl group having 1 to 8 carbon atoms, benzoyl, substituted benzoyl, alkylsulfonyl having 1 to 6 carbon atoms, phenylsulfonyl, or substituted phenylsulfonyl;


R^4 , R^5 , R^6 , R^7 , R^8 , and R^9 are each, independently, an acyl group having 1 to 6 carbon atoms; and

10 R^{10} and R^{11} are each, independently, an acyl group having 1 to 6 carbon atoms, or the R^{10} and R^{11} groups on the 4' and 6' positions of the maltose or the 4 and 6 positions of the glucose form an isopropylidene group;

or a pharmaceutically acceptable salt thereof.


15 37. The method of Claim 36 in which the condition which is characterized by excessive smooth muscle proliferation is restenosis.

38. A pharmaceutical composition comprising an effective amount of a compound of formula I



where X is

- 44 -



R^1 is H, alkyl having 1 to 6 carbon atoms, chloro, bromo, or alkoxy having 1 to 6 carbon atoms;

R^2 is H, an acyl group having 1 to 6 carbon atoms, phenylsulfonyl, or substituted phenylsulfonyl; and

R^3 is an acyl group having 1 to 8 carbon atoms, benzoyl, substituted benzoyl, alkylsulfonyl having 1 to 6 carbon atoms, phenylsulfonyl, or substituted phenylsulfonyl;

R^4 , R^5 , R^6 , R^7 , R^8 , and R^9 are each, independently, an acyl group having 1 to 6 carbon atoms; and

R^{10} and R^{11} are each, independently, an acyl group having 1 to 6 carbon atoms, or the R^{10} and R^{11} groups on the 4' and 6' positions of the maltose or the 4 and 6 positions of the glucose form an isopropylidene group;

or a pharmaceutically acceptable salt thereof.

INTERNATIONAL SEARCH REPORT

International App. No.

PCT/US 95/14795

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C07H15/203 A61K31/70

According to International Patent Classification (IPC) or to both national classification and IPC:

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 C07H A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	CARBOHYDRATE RESEARCH, vol. 151, 15 August 1986, AMSTERDAM NL, pages 371-378, XP000565755 U. ZEHAU & M. HERCHMAN: "Probing acceptor specificity in the glycogen synthase reaction with polymer-bound oligosaccharides." cited in the application see page 373	1
X	US,A,4 431 637 (UPESLACIS JANIS ET AL) 14 February 1984 see column 4	1
A	WO,A,90 06755 (GLYCOMED INC) 28 June 1990 see the whole document --- -/--	1,36,38

☒ Further documents are listed in the continuation of item C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *B* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *Z* document member of the same patent family

Date of the actual completion of the international search

17 April 1996

Date of mailing of the international search report

Name and mailing address of the ISA

European Patent Office, P.O. Box 5818 Patentplan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 631 cpo nl.
Fax (+31-70) 340-3016

Authorized officer

Moreno, C

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US 95, 4795

C. (Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of documents, with indications, where appropriate, of the relevant passages	Relevant to claim No.
A	EP, A, 0 356 275 (SANOFI SA) 28 February 1990 see the whole document ---	1,36,38
A	EP, A, 0 454 220 (AKZO NV ; SANOFI SA (FR)) 30 October 1991 see the whole document -----	1,36,38

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US 95/14795

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 36, 37
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claims 36 and 37 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US 95/14795

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US-A-4431637	14-02-84	NONE	
WO-A-9006755	28-06-90	US-A- 5032679	16-07-91
		AU-B- 634199	18-02-93
		AU-B- 4827490	10-07-90
		CA-A- 2005739	15-06-90
		EP-A- 0448637	02-10-91
		JP-T- 4503950	16-07-92
		US-A- 5380716	10-01-95
EP-A-0356275	28-02-90	FR-A- 2634485	26-01-90
		AT-T- 108804	15-08-94
		AU-B- 620632	20-02-92
		AU-B- 3885689	25-01-90
		DE-D- 68916878	25-08-94
		DE-T- 68916878	16-03-95
		ES-T- 2056239	01-10-94
		JP-A- 2073801	13-03-90
		OA-A- 9125	31-10-91
		PT-B- 91249	04-05-95
		SU-A- 1831487	30-07-93
EP-A-0454220	30-10-91	AU-B- 7525591	24-10-91
		CA-A- 2040905	24-10-91
		DE-T- 69100275	02-12-93
		ES-T- 2060284	16-11-94
		IL-A- 97904	31-07-95
		US-A- 5382570	17-01-95
		US-A- 5378829	03-01-95

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☒ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning these documents will not correct the image
problems checked, please do not report these problems to
the IFW Image Problem Mailbox.**